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Constraint-based genome-scale modelling is a widely used approach that facilitates 
computational exploration of biological networks of many organisms and diseases. This 
modelling approach is an efficient alternative to wet lab experiments for analysing cell 
metabolism and physiological functions. A plethora of constraint-based methods have 
been developed to facilitate a comprehensive analysis of these models. These methods 
can be applied to generate testable computational predictions and hypotheses. 
The work carried out in this thesis was focused on developing and analysing three 
genome scale constraint-based models for the normal fibroblasts (control), TGF-β-
stimulated-fibroblasts (myofibroblasts) and skeletal muscle cell. These models can 
provide valuable insight into the cell metabolic pathways and even study the 
metabolism of certain diseases. Fibroblast and myofibroblast models were compared to 
investigate the effects of TGF-β on cell proliferation, glycolysis and collagen synthesis. 
Having compared both models, the work then focused further on the myofibroblast 
model and investigated the metabolic pathways leading to collagen synthesis. Genes 
and reactions which are essential to collagen synthesis were identified. Most of the 
results generated by simulations were shown to support in vivo observations and could 
pave the way for identifying drug targets for patients with Idiopathic Pulmonary Fibrosis. 
In separate modelling, skeletal muscle simulations focused on studying the effects of 
hypoxia and amino acid supplementation on protein synthesis rate. This was with the 
view to providing valuable insights into metabolic requirements of muscle hypertrophy, 
possible causes (and treatments) of muscle atrophy, the cell responses to hypoxic 
stimulus and underlining the metabolic changes that occur in muscle during hypoxia. 
The modelling results showed that hypoxia directly impacts the protein synthesis rate 
and a metabolic switch from oxidative to glycolytic metabolism occurs. Furthermore, 
given the controversies surrounding amino acid supplements, studying the effects of 
amino acid supplementation on protein synthesis in silico can be an appropriate 
alternative to in vivo studies that aim at identifying the optimal combination of amino 
acids that could potentially trigger anabolic responses and increase protein synthesis in 
skeletal muscle. The results suggested that supplementation with certain combinations 
of amino acids could impact protein synthesis in muscle. Although further 
computational and experimental work may be required to verify these results, the 
current model predictions might pave the way for designing nutritional strategies that 
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The use of computational approaches in biology started in the 1960s with the advent of 
modern computers. These new approaches in biological studies were initially used for 
the computational interpretation of complex biochemical processes and to deal with 
increased amounts of experimental data (Hagen 2000). Nowadays, mathematical and 
computational methods are widely used tools in the study of biology. Systems biology is 
a multidisciplinary field of study that combines biological, mathematical and 
computational methods and techniques to provide a comprehensive exploration of 
complex biology systems (Friboulet et al. 2005).  
There are many approaches to understanding complex biological systems. Rather than 
studying isolated parts or components of a biological system, systems biology 
transcends reductionist views and uses a holistic approach to provide a comprehensive 
analysis at all levels. This “system-level” approach allows an integrative analysis of 
biological functions and organisms by revealing interactions among components within 
a system whilst describing the “whole picture”. Recent technological advancements in 
computer science and genome sequencing techniques which have resulted in large and 
complex data sets have also facilitated and driven the use of this integrative approach 
(Westerhoff et al. 2004). Furthermore, vast amounts of “omics” data generated from 
novel technologies such as genomics, transcriptomics, proteomics and metabolomics 
have the potential to provide a comprehensive view of the functioning biological 
systems and their integration (Westerhoff et al. 2004). To cope with ever larger data 
sets, sophisticated computational tools are required, which has been facilitated by a 
dramatic increase in processing power.  
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Several computational approaches exist in the field of systems biology. Among them, 
genome-scale constraint-based modelling (CBM) is a widely used approach to interpret 
and analyse “omics” data in a biochemically constructive manner. Genome-scale models 
coupled with constraint-based analysis tools provide context for “omics” data and have 
multiple applications (Oberhardt et al. 2009) including model-driven hypothesis 
formulation (Ibarra et al. 2002), strategies for metabolic engineering (Kim et al. 2015), 
and in silico drug discovery (Folger et al. 2011). These models provide an efficient 
alternative to the study of metabolism in organisms or tissues and metabolic 
interactions associated with diseases (Vo et al. 2007, Bordel 2018). The overall aim of 
the work presented in this thesis is to use several constraint-based approaches to build 
and analyse two separate genome-scale metabolic models of two human contractile 
cells: myofibroblasts and skeletal muscle cells. 
Myofibroblasts are contractile cells that are phenotypically situated between fibroblasts 
and smooth muscle cells and play a crucial role in the process of wound healing. 
Myofibroblast cells migrate to the sites of injury where they produce collagen and 
eventually contract the wound. Furthermore, their sustained presence at the site of 
injury and uncontrolled proliferation are suspected to be the main causes for fibrotic 
diseases.  
Skeletal muscle cells are another essential contractile cell type, enabling movement, 
maintenance of body posture, breathing, etc. These cells are responsible for rapid and 
forceful contractions of short durations. Any loss of skeletal muscle mass or function is 
suspected to be determined by a lack of equilibrium between muscle protein synthesis 
and breakdown rates (McKinnell et al. 2004). Clinically, this can happen in conditions 
such as sarcopenia, chronic obstructive pulmonary disease (COPD) or cancer (Passey et 
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al. 2016). It can also occur in healthy people under environmental hypoxia. For instance, 
it was reported that loss of muscle mass can occur in mountain climbers  (Boyer et al. 
1984, Rose et al. 1988).  
Despite some commonalities in their contractile phenotype, these cells have very 
different physiology and metabolic requirements. They are also both important to 
several phenotypes and diseases. The reconstruction and analysis of the genome-scale 
models for these two cells can produce meaningful insights into their metabolic 
capacities with therapeutic potentiality. Hopefully, model-driven predictions that are 
experimentally validated could be used for designing optimal patterns of nutrient supply 
or identify candidate drug targets.  
Thus, the work presented here seeks to use constraint-based modelling approaches to 
reconstruct and analyse the genome-scale metabolic networks for these contractile 
cells. 
1.2 Literature review 
This literature review aims to consider a number of areas that are pertinent to genome-
scale CBM and a general description of the organisms that are reconstructed using 
constraint-based methods. It will give a brief review of metabolism, metabolic pathways, 
metabolic network reconstruction, systems biology and CBM approaches. Lastly, this 
section provides a description of the biological relevance of the fibroblasts, 
myofibroblasts and skeletal muscle cells, the cells types which are the focus of the 




Metabolism is the set of chemical reactions that produce energy and maintain life in an 
organism. Metabolism can be divided into two overarching processes: catabolism and 
anabolism. Catabolism is the process of degrading larger molecules into smaller ones. 
This process generates energy which is ultimately stored in the form of adenosine 
triphosphate (ATP), an exergonic process. On the other hand, anabolism uses energy to 
build up more complex molecules from simple precursors, an endergonic process. 
Chemical reactions are usually catalysed by enzymes and these play a crucial role in both 
catabolism and anabolism. Enzymes are proteins that lower the activation energy for 
certain reactions, and thus increase the rate at which these reactions occur (Cooper 
2000). Without the intervention of enzymes, many reactions would happen at very low 
rates and life could not be maintained (Wolfenden et al. 2001).  
Morphologically, enzymes are composed of large chains of amino acids (AAs) which fold 
up into a tertiary structure. During the process of translation, the information contained 
in the messenger ribonucleic acid (mRNA) is translated into a sequence of AAs (Kuchel 
1998) to form proteins. This is preceded by transcription:  the copying of genetic 
information from DNA sequence to mRNA. In eukaryotic cells these processes occur one 
after the other and in different places within the cell: Transcription occurs in the nucleus, 
while translation takes place in the cytoplasm. On the other hand, in prokaryotic cells, 
these processes are closely connected and happen in the same cell compartment. 
Furthermore, in prokaryotic cells translation can begin while transcription is still 
happening (Berg et al. 2002). Taken together (transcription and translation), this two-
step process, is also known as the central dogma in molecular biology (Crick 1970) and 
it describes a directional flow of information from DNA to RNA and from RNA to proteins. 
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1.2.1.1 Metabolic pathways  
In order to convert one metabolite into another, a series of enzyme-catalysed reactions 
may be required. Metabolic pathways are useful tools for illustrating this process. In this 
framework, metabolic pathways can be defined as a sequence of successive reactions 
that connect metabolites (Kremling 2013). Metabolic pathways can be linear, branched 
(convergent or divergent) cyclic or spiral (Fig. 1.1).  
  
Figure 1.1 Patterns of metabolic pathways 
Metabolic pathways can be linear, cyclic, branched or spiral. In linear metabolic pathways, a 
compound is transformed into another through a series of intermediate reactions. Branched 
pathways can be either convergent (several compounds combine to produce a single compound 
further along in the pathway) or divergent (an intermediate compound can yield several end 
products). In cyclic pathways, the final compound is the same as initial substrate and 
intermediates are regenerated at every step. In spiral pathways, the same enzymes catalyse a 
series of reactions that are used to build up or break down a certain compound. Adopted from 
(Boyer 2001) Copyright ©2002 Wadsworth Group, a division of Thomson Learning, Inc. 
 
Primary metabolism consists of several core reactions that are necessary for maintaining 
life. Thus, there are a number of metabolic pathways that are common among most 
organisms. Examples of such pathways include glycolysis, tricarboxylic acid (TCA) cycle 
or pentose phosphate pathway.  
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Metabolic pathway analysis allows an accurate investigation of the structural and 
functional properties of the metabolic network (Schilling et al. 1999) and can be used to 
identify meaningful routes within the network (Rugen et al. 2012).  With the advent of 
network reconstructions and genome-scale metabolic models, metabolic pathway 
analysis can be integrated with constraint-based approaches such as Flux Balance 
Analysis (FBA) (Orth et al. 2010) to assess the impact of various genetic and 
environmental perturbation on the entire network (Schilling et al. 2000). These 
approaches have enabled a better understanding of metabolic capabilities and 
limitations for several organisms (Schilling et al. 2000) and will be described in detail in 
sections 1.2.3-1.2.4. 
 
1.2.2 Systems biology concepts 
Systems biology is a multidisciplinary field that combines mathematical, computational 
and experimental approaches to explore various biological systems (Edwards 2017). At 
the core of this field is the use of holistic instead of reductionist concepts when studying 
a complex biological system. A system can be defined as a collection of interacting 
elements that form an integrated whole. A reductionist view aims to divide a system 
into constituent parts and study them separately. Its historical roots can be traced back 
to the late 17th century when many scientific discoveries were based on this approach 
(Trewavas 2006). On the other hand, a holistic view describes systems “as a whole” by 
considering the interactions between the constituent components. In general system 
theory, a holistic approach is closely related to the concept of emergence (von 
Bertalanffy 2003). A system’s emergent properties do not belong to any individual part 
of the system but arise from the system as a whole (Kesić 2016). Thus, systems biology 
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aims to study an organism as an integrated system of interacting components rather 
than focusing on individual parts.  
Developments in molecular biology have led to a transition from a reductionist view on 
biological systems, to a more integrative approach (Ge et al. 2003). Scientists became 
able to study the interactions that define cellular processes. Furthermore, the advent of 
genome-sequencing techniques contributed highly to this transition (Westerhoff et al. 
2004). High-throughput “omics” technologies such as genomics, transcriptomics, 
proteomics and metabolomics allow the combined analysis of several classes of 
molecule such as DNA, RNA, proteins and metabolites. These highly-parallel 
technologies permit the simultaneous interrogation of different molecules of the same 
cell (Fischer 2008) and provide a comprehensive view of biological systems (Robinson et 
al. 2016). A system-level view of biological systems can bridge the genotype-phenotype 
gap. 
One of the most important challenges in biology is understanding the genotype-
phenotype relationship. This relationship describes the impact of variations in genome 
on various functional phenotypes. This is a complicated concept, and although some 
attempts have been made to formalise this relationship and characterize the two 
biological components simultaneously (Alberch 1991), not many consistent results have 
been obtained. This difficulty could be attributed to the complexity of biological 
systems. However, technological advancements in genome sequencing techniques and 
the generation of genome-wide data have now facilitated the development of biological 
networks which provide a mechanistic framework for encoding the genotype-
phenotype relationship (Lewis et al. 2012). 
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With the increased number of large datasets containing genome-wide information, 
advanced mathematical and computational tools are needed for processing, integrating 
and analysing the data. Biological networks provide a platform for integrating “omics” 
data and facilitate computational investigation of the biological systems. These 
networks can successfully replicate a biological system of interacting components. 
Furthermore, biological networks can be converted into mathematical models that 
allow computational analysis and in silico simulations. Many types of molecular 
networks can be distinguished: metabolic, protein-protein interaction, signalling and 
gene regulatory networks (Mahadevan et al. 2005).   Among all types of biological 
networks, metabolic networks are the most widely studied due to their unique 
properties and applications (Pfeiffer et al. 2005, Edwards 2017). These properties and 
applications will be described in the next section. 
1.2.3  Metabolic networks 
Metabolism can be described by a complex network of chemical processes. Metabolic 
networks consist of metabolites, chemical reactions that produce metabolites, enzymes 
that catalyse reactions and genes that encode various enzymes. Thus, a metabolic 
network is essentially an interconnected network of metabolites, reactions and enzyme-
coding genes. Metabolic networks can be represented by a directed graph where nodes 
are represented by metabolites, and edges represent reactions (Fig. 1.2). The structure 
is different from signalling or protein-interaction networks where substrates and 
enzymes are not separated, and edges are determined by interactions and describe 
whether an interaction is present or absent. The separation between reactions and 
metabolites in the metabolic networks allows the conservation of mass or energy at 
every node by imposing physicochemical constraints such as the mass or energy balance 
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equations. Thus, the unique properties of metabolic networks are determined by their 
structure and are described by the separation between enzymes and substrates and the 
conservation constraints that could be imposed at every node (Mahadevan et al. 2005). 
 
Figure 1.2 Metabolic pathways in the form of directed graph 
Metabolic networks in the form of directed graphs comprised of edges to represent reactions 
and nodes to represent metabolites.   
 
Genome-scale metabolic networks are typically converted into a mathematical model 
that facilitates the computational investigation. Once a metabolic network is converted 
into mathematical model, its functional states (phenotypic functions) can be 
investigated using graph methods or constraint-based approaches such as FBA (Orth et 
al. 2010). Details about network reconstruction process and modelling approaches are 
further discussed in sections 1.2.3.1-1.2.3.2 and 1.2.4. 
1.2.3.1 Metabolic network reconstruction 
A prerequisite for developing a model of a target organism is the reconstruction of a 
genome-scale metabolic network. There are essentially two approaches in the 
reconstruction process: inference-based and knowledge-based (Hyduke et al. 2013, 
Katze 2013). Inference-based reconstruction uses statistical approaches to estimate and 
infer unknown interactions in the network, based on interaction patterns in high-
throughput data. However, there are certain limitations of the inference methods 
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(Margolin et al. 2007). For instance, the inference network problem is underdetermined, 
or, in other words, it has an infinite number of solutions. Thus, many solutions can match 
the available experimental data, but not all of them can be biologically relevant (De Smet 
et al. 2010).  
Knowledge-based reconstructions are built using curated genomic and metabolic data 
that are based on the annotated genome and experimental information from literature.  
In other words, metabolic network reconstructions detail the known metabolic 
reactions in an organism and the genes that encode each enzyme. The genotype-
phenotype relationship is described by Gene – Protein – Reaction (GPR) associations 
that match genes to enzymes and enzyme-catalysed reactions (Fig.1.3). Hence, genetic 
data is mapped to flux data and one can assess the effect of genetic perturbations on 
various phenotypes. In a metabolic network reconstruction, Boolean logic is used to 
represent the GPR associations (Fig. 1.4). 
 
Figure 1.3 Gene-protein-reaction (GPR) relationship 
An example of GPR relationship from a genome-scale-metabolic network. Genes are matched to 






Figure 1.4 GPR and Boolean logic  
Boolean operators (AND, OR) can be used to describe the GPR associations. Adapted from Jensen 
et al. (2011) 
 
Reconstruction of metabolic networks is a complex, laborious and iterative process. In 
2010 a protocol for metabolic network reconstructions was published (Thiele et al. 2010) 
and divided the entire process into 96 steps and 4 stages. Furthermore, the time for 
constructing a comprehensive metabolic network was estimated to last from 6 to 24 
months. 
Genome-scale metabolic reconstructions have been extensively used for studying 
various organisms from prokaryotic cells to eukaryotic ones. Since the first metabolic 
reconstruction in 1999 (Edwards et al. 1999) various cells and tissues have been 
reconstructed (Forster et al. 2003, Borodina et al. 2005, Beste et al. 2007, Jamshidi et al. 
2007, Oh et al. 2007). Once assembled, the reconstruction can be easily converted into 
a mathematical format (in silico model) that facilitates the computational investigation 
of several biological functions.  
The first genome-scale reconstruction of the global human metabolic network (Recon 1) 
was published in 2007 (Duarte et al. 2007). In the same year, Edinburgh Human 
Metabolic Network (Ma et al. 2007), a second global reconstruction of the human 
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metabolic network was published too. Recon 1 contains physiological and biochemical 
information for 1,496 genes, 2,004 proteins, 2,766 metabolites, and 3,311 reactions. 
More than 1500 scientific publications were used to build Recon 1. Furthermore, this 
network reconstruction was transformed into a computational format (in silico model) 
and the simulation of 288 metabolic functions of different cells or tissues was used to 
validate this human metabolism model (Duarte et al. 2007). Since the first 
reconstruction in 2007, several updates have been published and they were 
incorporated in different versions of the global human metabolic reconstruction. Five 
detailed and complete reconstructions of the human metabolism are available to date: 
Recon 1 (Duarte et al. 2007), Recon 2 (Thiele et al. 2013), Recon 2.1 (Smallbone, K. 2013),  
Recon 2.2 (Swainston et al. 2016) and Recon 3D (Brunk et al. 2018). 
Recon 2, published in 2013, was an extension of Recon 1 with significant improvements 
in terms of information coverage and functional properties. Recon 2 was more 
comprehensive than Recon 1, accounting for 1789 genes, 7740 reactions and 2626 
unique metabolites. Recon 2 also reduced the number of blocked reactions (827 in 
Recon1 compared to 441 in Recon 2) and dead-end metabolites. In this framework, 
dead-end metabolites represented those metabolites which were either produced or 
consumed in only one reaction. Furthermore, a full set of metabolic tasks (metabolic 
functions such as biomass, ATP production etc) were fulfilled by Recon 2, while Recon 1 
only managed to fulfil 63% of them. Apart from the improved metabolic coverage, Recon 
2 also displayed advanced predictive capabilities when compared to Recon 1. Recon 2 
successfully predicted more biomarkers for several inborn errors of metabolism (IEMs) 
and with higher accuracy when compared to Recon 1. In brief, the concept of predicting 
metabolite biomarkers for IEMs using metabolic networks refers to the analysis of the 
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exchange reaction fluxes and their comparison with the metabolite levels in the 
experimental data (Shlomi et al. 2009). Recon 2.1, an updated version of Recon 2, 
resolved several unbalanced reactions present in the previous reconstruction. These 
unbalanced reactions could lead to growth being simulated without any carbon source. 
However, Recon 2.1 couldn’t resolve the mass and charge imbalances for every reaction 
in the reconstruction. Therefore, there was a need for a more developed reconstruction 
to amend these issues. Recon 2.2 integrated the Recon 2 updates that were previously 
published, ensured the mass and charge balance for all reactions and provided a better 
representation of the energy metabolism. ATP synthesis incorporated carbon availability 
and fatty acid oxidation (both mitochondrial and peroxisomal) was expanded. A new 
compartment, mitochondrial intermembrane space, was created to incorporate a 
proton gradient. In the previous reconstructions, protons were only represented as 
cytosolic protons. Hence reactions in the respiratory chain and aspartate-glutamate 
shuttle which involved proton transportation were updated with intramembrane 
protons. A combination of manual and semi-automatic curation was performed, leading 
to a comprehensive model consisting of 7785 reactions, 1675 genes and 5324 
metabolites. Recon 2.2, the main reconstruction used for the modelling work 
undertaken in this thesis, was the most up to date reconstruction available when this 
project began. Since then, a more developed reconstruction has been published: Recon 
3D, the latest version of the global human reconstruction, was published in 2019 and 
accounted for 3288 genes, 13543 reactions, 4140 metabolites and 12890 protein 
structures. This makes Recon 3D the most comprehensive metabolic human 
reconstruction to date. Recon 3D also provides the three-dimensional structure of 




By using either manual or automated approaches, these global metabolic models can be 
coupled with high-throughput “omics” data such as transcriptomics, metabolomics or 
proteomics, to generate tissue and cell-specific models (Agren et al. 2012, Wang et al. 
2012). For example, gene expression data for a certain cell or tissue can be integrated 
with the global metabolic reconstruction to determine cell-specific reactions. Coupling  
“omics” data with generic metabolic models has led to the development of several cell 
or tissue specific models (Bordbar et al. 2010, Chang et al. 2010, Gille et al. 2010, Jerby 
et al. 2010) and cancer specific models (Folger et al. 2011, Frezza et al. 2011, Jerby et al. 
2012, Nilsson et al. 2017). The most common approach involves a combination of 
manual and automated methods and several algorithms have been developed for this 
purpose: GIMME (Becker et al. 2008), MBA (Jerby et al. 2010) , FASTCORE (Vlassis et al. 
2014) or FASTCORMICS (Pacheco et al. 2015).  
The GIMME algorithm initially considers a gene expression data set, a global metabolic 
reconstruction and certain biological functions as the main inputs. Reactions 
corresponding to a gene expression below a predefined threshold are declared inactive 
and removed from the network. The algorithm then optimizes for a specific biological 
function (objective function) such as ATP production or growth, etc. If the network fails 
to fulfill this required biological function, some reactions that were previously removed 
are reactivated subject to a minimal inconsistency with the gene expression data.  
MBA considers a core set of highly active reactions, a second core set of medium 
confidence reactions, and tries to find a feasible network which contains the entire first 
set, a maximum number of the second set (if a specific trade-off is met) and a minimal 
number of reactions from the global human reconstruction. MBA is essentially pruning 
all reactions from the human reconstruction which do not support those reactions in the 
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first and second set. It is important to point out that MBA has very high computational 
demands. 
Similar to MBA, the FASTCORE algorithm considers a core set of reactions and aims to 
use a minimum number of reactions from the global human reconstruction to create a 
context-specific model while trying to include all reactions from the core in the final 
model. Unlike MBA which uses pruning, the search for a minimal solution is done using 
the L1-normalisation, minimising the L1 norm of the vector of fluxes in the non-core set. 
The non-core set is essentially included in a “penalty” set and L1 normalisation is used 
to minimise fluxes in this set. This method significantly increases the speed of the 
algorithm.  
FASTCORMICS is essentially a workflow that uses FASTCORE algorithm for model 
generation with a different discretization for gene expression and considers a “non-
penalty set” for certain reactions. It is also important to keep in mind, that one idea of 
FASTCORE is to not add unnecessary reactions, and generate a small model of highly 
active metabolism, rather than a large one, where some reactions would need to be 
restricted to very low bounds because there is almost no enzyme expression to catalyse 
them. The idea of FASTCORMICS is to get rid of those reactions, which would be included 
in the model just because they are: i) catalysed by promiscuous genes, ii) transporters, 
iii) part of cyclic pathways, or iv) involved in shorter pathways for producing metabolite 
B from metabolite A despite the contradicting information from omics data. 
FASTCORMICS does not remove these reactions directly but assigns them to a “non-
penalty set” which is removed from the core set but favoured over the the non-core set. 
FASTCORMICS is the workflow chosen for the modelling work in this thesis. Thus, a more 
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detailed description of the FASTCORE algorithm and FASTCORMICS workflow is included 
in the Methods chapter, section 2.2.4. 
FASTCORE is a very restrictive algorithm and it will only allow reactions which are 
necessary for the use of the core to stay in the model. This is similar to the concept that 
MBA uses, while GIMME only removes reactions if they are actively unsupported, and  
relies a lot on the objective function selected. With GIMME, consistency is defined by 
the feasability of the objective function. This means that reactions which might not be 
relevant for a certain organism may be wrongly added to the model. FASTCORE does not 
require an objective function in the form of a biological function and the only 
mathematical objective is network consistency. The result of FASTCORE algorithm is not 
a flux distribution, but a set of reactions which are required so that all core reactions are 
able to carry a minimal flux. In the end, every algorithm has its advantages, but it is the 
author’s opinion that FASTCORE/FASTCORMICS provides a solid basis for further 
curation in comparison with most of other algorithms in which retained reactions could 
also be unrelated to the organism being studied.  
1.2.3.2 Conversion of metabolic network reconstruction to a computational format  
Before a metabolic network can be investigated with computational approaches, it must 
be converted into a mathematical format. The stoichiometric matrix is the mathematical 
representation of the metabolic network reconstruction and the central component of 
genome-scale metabolic models. In this framework, the metabolic network is 
represented by a stoichiometric matrix 𝑺𝑺𝒂𝒂𝒂𝒂 with 𝒂𝒂 metabolites and 𝒂𝒂 reactions. The 
dimension of the matrix is 𝒂𝒂 𝒙𝒙 𝒂𝒂 where 𝒂𝒂 is the number is the number of rows and b is 
the number of columns. In the matrix 𝑺𝑺𝒂𝒂𝒂𝒂 each entry 𝒔𝒔𝒂𝒂𝒂𝒂 represents the stoichiometric 
coefficient of metabolite 𝒂𝒂 in reaction 𝒂𝒂. All the reactions in the matrix are represented 
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by the flux vector 𝒗𝒗𝒂𝒂 which has the dimension equal to the number of reactions. The 
following simple ordinary differential equation represents the rate of change in the 
concentration of a metabolite over time: 
𝒅𝒅𝒅𝒅
𝒅𝒅𝒅𝒅
 =  𝑺𝑺𝒗𝒗 (𝟏𝟏.𝟏𝟏) 
where 𝒅𝒅  is the vector of metabolite concentrations with dimension 𝒂𝒂, 𝑺𝑺 is the 
stoichiometric matrix with dimension 𝒂𝒂 𝒙𝒙 𝒂𝒂, and 𝒗𝒗 the flux vector with dimension 𝒂𝒂.  
The rate of change in the metabolite concentration is usually dependent on kinetic 
parameters. However, data regarding these time-variant parameters is scarce and their 
measurement is challenging (O'Brien et al. 2015). The assumption of steady state 
bypasses this obstacle and allows an investigation of the large networks based solely on 
reaction stoichiometry at steady states. For any internal metabolite, consumption and 
production rates are equal and the stoichiometric matrix can be divided into two 
sections (Fig. 1.5). 
The steady-state assumption under mass conservation law is usually written as a mass 
balance equation and represents a constraint imposed on the genome-scale network. 
The imposition of further constraints constitutes the basis for CBM. This modelling 







Figure 1.5 A metabolic network in steady state and its associated stoichiometric matrix 
Aext, Bext, Cext and Dext represent the external metabolites, while A, B, C and D represent the internal 
metabolites. R1, R2, R3, R4 represent the boundary fluxes while V1, V2, V3, V4 represent the 
internal fluxes. 
 
1.2.4 Constraint-based modelling  
1.2.4.1 Introduction to constraint-based modelling 
According to Charles Darwin, organisms exist in a resource-limited environment and 
natural selection favours those who adapt to this environment (Darwin, 1859). 
Environmental pressure and resource allocation trade-offs shaped cellular behaviour 
during evolution. To optimise their resources and limit possible phenotypes, cells must 
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impose several constraints on themselves (Covert et al. 2003). Thus, constraints are 
essential for limiting cellular behaviour and defining achievable phenotypes (Palsson et 
al. 2015). When applied to reconstructed biological networks such as metabolic 
networks, a constraint-based approach can be useful for analysing the feasible 
functional states of the network, given a set of constraints (Bordbar et al. 2014). This 
approach leads to the computational investigation of reconstructed networks by using 
several constraint-based methods and techniques. 
1.2.4.2 Constraint-based approaches 
In a genome-scale metabolic network, the assumption of steady state implies that the 
rate of change for metabolites remains constant over time or, in other words, the rate 




 = 𝟎𝟎 and equation 1.1 can be written as: 
𝑺𝑺𝒗𝒗 =  𝟎𝟎 (𝟏𝟏.𝟐𝟐)   
It is important to point out that, in a genome-scale model, the number of reactions or 
fluxes is greater than the number of metabolites. Thus, equation 1.2 can be written as a 
system of 𝒂𝒂 equations with 𝒂𝒂 unknown variables. This system of linear equations has no 
unique solution and all possible solutions are said to be in the null space of matrix S 
(Orth et al. 2010). The null space represents the solution space for the flux vector 𝒗𝒗. In 
reality, not all solutions can be achieved as organisms are limited by certain constraints 
(Price et al. 2004). Therefore, additional constraints can be imposed to reduce the size 
of the solution space and limit the range of possible cellular behaviours. In this 
framework, several types of constraints can be distinguished: physicochemical, 
environmental, topological and gene regulatory (Price et al. 2004). From another 
perspective, constraints can be classified into “adjustable” and “non-adjustable” 
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constraints, based on their ability to adapt to evolutionary changes (Palsson 2000). Non-
adjustable constraints are based on flux capacity, network topology and reaction 
reversibility (Covert et al. 2003). Physicochemical constraints fall in this category and 
they are associated with most genome-scale models. Adjustable constraints, such as 
gene regulatory ones, are used in second-generation models to further limit the solution 
space and describe the evolutionary cell behaviours (Covert et al. 2003, Palsson 2015). 
Cells receive signals from the extra- or intracellular environment, which determines 
changes in the expression of genes. In this way, cells adapt to environmental changes 
and these regulatory events may underlie optimal evolutionary behaviour. Gene 
regulatory constraints used in second-generation models are self-imposed by the cell, 
time-variant and dependent on certain biological circumstances (Covert et al. 2003).  
Most commonly, physicochemical constraints are mathematically represented in the 
form of balances and bounds (Orth et al. 2010). Mathematically, balances are 
represented by equations, while bounds are imposed in the form of inequalities. For 
instance, equation 1.2 is called the mass balance constraint. Upper and lower bounds 
can be set to limit the flux capacity or change the reversibility of certain reactions: 
𝑙𝑙𝑖𝑖  ≤  𝑣𝑣𝑖𝑖  ≤  𝑢𝑢𝑖𝑖 ∀ 𝑖𝑖 ∈  𝑁𝑁 where 𝑣𝑣𝑖𝑖 represents the flux vector, 𝑙𝑙𝑖𝑖 and 𝑢𝑢𝑖𝑖 represent the 
lower and upper bound respectively and 𝑁𝑁 represents the set of natural numbers. 
These bounds constrain the uptake or production rates for certain compounds. The 
values for rates are usually collected from the literature and they are based on 
experimental information. Constraints limit the solution space and the system of linear 
equations derived from equation 1.2 can be solved using linear programming (LP). A LP 
problem can be defined as the process of optimising a linear function given a set of 
constraints. Optimisation typically means maximisation or minimisation of a linear 
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function. Constraints usually take the form of linear equalities of inequalities and the 
linear function is often called the objective function. Here is an example for a typical LP 
problem: 
Determine 𝑎𝑎1 and 𝑎𝑎2 to maximise 2𝑎𝑎1  +  𝑎𝑎2 given the following constraints:  
𝑎𝑎1  +  2𝑎𝑎2  ≤  8 
2𝑎𝑎1  +  4𝑎𝑎2  ≤  14 
This simple example can be generalised. The generalisation is known as the General 
Standard Linear-Programming Problem (Bertsimas et al. 1997, Gass 2003). 









𝑖𝑖 = 1,2, … ,𝑚𝑚 
𝑎𝑎𝑛𝑛𝑎𝑎 
𝒙𝒙𝒋𝒋 ≥ 𝟎𝟎    𝑠𝑠 = 1,2, … ,𝑛𝑛 
A standard LP problem can be solved by using the simplex method. Dantzig’s simplex 
method (Dantzig et al. 1987) is an algorithm for solving linear problems. It can be 
implemented computationally, and has a wide range of applications (Gass 2003) 
including FBA (Orth et al. 2010). Thus, once bounds and balances are imposed and the 




𝑚𝑚𝑎𝑎𝑚𝑚𝑖𝑖𝑚𝑚𝑖𝑖𝑠𝑠𝑚𝑚 𝑡𝑡𝑜𝑜 𝑚𝑚𝑖𝑖𝑛𝑛𝑖𝑖𝑚𝑚𝑖𝑖𝑠𝑠𝑚𝑚  𝑍𝑍𝑜𝑜𝑜𝑜𝑗𝑗 =  𝑐𝑐𝑡𝑡𝑣𝑣 
𝑆𝑆𝑢𝑢𝑠𝑠𝑠𝑠𝑚𝑚𝑐𝑐𝑠𝑠 𝑠𝑠𝑡𝑡: 
𝑆𝑆𝑣𝑣 =  0 
𝑙𝑙𝑖𝑖 ≤  𝑣𝑣𝑖𝑖 ≤  𝑢𝑢𝑖𝑖 (𝐿𝐿𝐿𝐿 1.1) 
Where 𝑣𝑣𝑖𝑖 represents the flux for reaction 𝑖𝑖, 𝑐𝑐 represents the row vector of weighting 
coefficients for fluxes in 𝑣𝑣. The objective function 𝑍𝑍𝑜𝑜𝑜𝑜𝑗𝑗 is written as a linear combination 
of fluxes i.e. 𝑍𝑍 = ∑ 𝑐𝑐𝑖𝑖𝑣𝑣𝑖𝑖𝑖𝑖 . This LP problem can be solved computationally by using 
existing algorithms and packages. These packages are further discussed in Chapter 2. 
 
 
Figure 1.6 Constraints and Flux Balance Analysis 
The steady-state constraint is imposed in the form of a mass balance equation. The imposition 
of upper and lower bounds for each reaction limits the solution space and FBA can be employed 
to find an optimal solution v to maximise Z within the bounded solution space. Adopted from 
Orth et al. (2010). 
  
FBA seeks to optimise a certain biological function (objective function) given a set of 
metabolic constraints. These objective functions can include biomass or cell growth 
(Edwards et al. 2000, Forster et al. 2003, Feist et al. 2007), ATP production (Ramakrishna 
et al. 2001, Vo et al. 2004), or nutrient uptake (Schwender 2008). The most common 
objective function is the biomass yield which simulates growth of an organism. Biomass 
or cell growth is usually associated with microorganisms as they have a high proliferation 
rate (Agren et al. 2012). However, a biomass objective function was used to simulate 
growth/proliferation for other cells too, e.g. cancer cells (Bordel 2018), macrophages 
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(Bordbar et al. 2010) or fibroblasts (Vo et al. 2007). A biomass objective function takes 
the form of a stoichiometrically balanced reaction which contains the energy 
requirements and building blocks that are essential for an organism to grow.  
1.2.4.3 Constraint-based methods 
FBA (Orth et al. 2010) is a common approach used in CBM. When FBA is employed and 
biomass maximised or minimised, one can analyse the biosynthesis and conversion of 
certain biomass compounds that are required for optimising this function. Optimising 
cell growth using a biomass objective function has produced results consistent with 
experiments. For instance, in a study published in 2001, the biomass objective function 
was maximised and the results suggested that Escherichia coli uses its metabolism to 
reach maximal growth which is consistent with experimental data (Edwards et al. 2001). 
Furthermore, in another study which used biomass to simulate growth, the modelling 
work predicted the substrates along with the reactions and genes required for the 
growth of H. pylori with significant accuracy (Schilling et al. 2002).  
One of the most important FBA-related applications is Gene Essentiality Analysis (GEA) 
(Edwards et al. 2000). This promising tool is FBA-based and uses computational 
approaches to study in silico genetic perturbations. GEA performs single-gene deletion 
to assess the essentiality of certain genes to biomass yield or other cellular functions, 
depending on the organism being analysed. FBA-based GEA produced results that were 
consistent with experimental data such as the identification of the essential genes for 
growth (Edwards et al. 2000). It is important to point out that FBA assumes an optimal 
growth. Thus, FBA-based GEA generates accurate predictions for wild-type strains but it 
is less accurate for genetically or environmentally perturbed strains that typically display 
sub-optimal growth (Segrè et al. 2002). MOMA (Segrè et al. 2002) was developed to 
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predict mutant fluxes by finding an approximate sub-optimal flux distribution, while 
minimising the difference between the wild-type and mutant optimum. Synthetic 
lethality analysis is performed in a similar way to assess synthetic interactions of genes. 
Synthetic Lethal (SL) genes were initially defined as those genes whose simultaneous 
knockout is lethal or prevents growth of an organism (Novick et al. 1989, Guarente 
1993). Pairs (or more) of non-essential genes can be simultaneously deleted to assess 
their effect on growth rate or other cellular functions. Although some genes may be 
identified as dispensable in GEA, the combined knockdown of two non-essential genes 
could be lethal to the chosen objective function.  
By using these methods, one can evaluate the impact of gene deletions on the FBA flux 
rate for a reaction of interest. Genes whose knockdowns significantly impact the 
production rate of a certain metabolite can be considered for designing nutritional 
strategies or predicting drug targets. A study proposed in 2011 (Folger et al. 2011)  
produced a genome-scale metabolic network of cancer metabolism. Using gene deletion 
and a biomass objective function to simulate growth, the model predicted 52 cytostatic 
drug targets with 40% of these targets being already used in either approved or 
experimental treatments. By using FBA-based GEA, common and novel cancer-specific 
drug targets were also identified in related work (Tobalina et al. 2016). Furthermore, in 
one reconstruction of Mycobacterium tuberculosis similar approaches were used to 
identify drug targets  with a prediction accuracy of 78% (Beste et al. 2007).  
It is worth mentioning that the implementation of these tools is based entirely on 
computational methods. Thus, further experimental validation may be required to 
investigate accuracy of results. 
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LP problems can result in multiple optimal solutions for the same objective function. 
One of the limitations of FBA is that it provides a single optimal solution when an 
objective function is either maximised or minimised. Some of the alternative optimal 
solutions can be physiologically meaningful (Reed et al. 2004). Thus, variability of 
optimal solutions should be assessed (Lee et al. 2000). Flux Variability Analysis (FVA) is 
a widely used LP approach that calculates minimum and maximum range of fluxes for 
each reaction flux given a set of constraints and a target objective function. FVA solves 
two LP problems (a maximisation followed by a minimisation) and can be written as:  
𝑀𝑀𝑎𝑎𝑚𝑚/𝑀𝑀𝑖𝑖𝑛𝑛 𝑣𝑣𝑖𝑖 𝑠𝑠𝑢𝑢𝑠𝑠𝑠𝑠𝑚𝑚𝑐𝑐𝑠𝑠 𝑠𝑠𝑡𝑡:  
𝑆𝑆𝑣𝑣 =  0 
𝑍𝑍 = 𝑢𝑢𝑡𝑡𝑣𝑣 ≥ 𝛼𝛼𝑍𝑍0 𝑓𝑓𝑡𝑡𝑜𝑜 0 ≤  𝛼𝛼 ≤  1   
𝑙𝑙𝑖𝑖 ≤  𝑣𝑣𝑖𝑖 ≤  𝑢𝑢𝑖𝑖 (𝐿𝐿𝐿𝐿 1.2) 
Where 𝑍𝑍0 = 𝑢𝑢𝑡𝑡𝑣𝑣0 represents the objective function from LP 1.1. The formulation of LP 
1.2 was obtained from Gudmundsson et al. (2010). It is important to point out that FVA 
does not assess all possible optimal solutions (Mahadevan et al. 2003). However, it 
provides valuable insight into network flexibility and robustness (Gudmundsson et al. 
2010).  
Having described the principles and concepts behind COBRA approaches, the next part 




1.2.5 Biology of the fibroblasts, myofibroblasts and skeletal muscle cells 
1.2.5.1 Fibroblasts and myofibroblasts 
1.2.5.1.1 Wound healing 
The wound healing process has been thoroughly studied since the beginning of human 
civilisation. For instance, one of the oldest medical records, a clay tablet dated 2200 BC 
provides a set of procedures for wound care: “washing the wounds, making the plasters 
and bandaging the wound“ (Shah 2011). Wounds can occur in many tissues types but 
most of them undergo similar phases in repairing and healing. Typically, normal wound 
healing is comprised of three stages: inflammatory, proliferative and maturation (also 
known as remodelling). These stages may, to some extent, overlap one another 
(Gonzalez 2016). 
Wound healing is a dynamic and complex biological process that generates a cascade of 
cellular and biochemical events. It involves several different cell types and the activation 
of multiple metabolic pathways. For many years, the research community’s focus was 
on developing empirical therapeutic strategies rather than understanding the biological 
mechanisms behind the process of wound healing. More recently, researchers have 
studied several of the physiological aspects involved in wound healing (Bochaton-Piallat 
2016). It is now generally accepted that fibroblastic cells acquire contractile features 
during normal and pathological tissue repair processes as they differentiate into 
myofibroblasts playing a central role in wound contraction and scarring. This has opened 
a new perspective in the understanding of the physiological mechanisms involved in this 
complex biological process. 
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1.2.5.1.2 The fibroblast  
Fibroblast cells are the most common cells in connective tissue. These cells support the 
structural framework of tissues by actively producing extracellular matrix (ECM) 
proteins. Fibroblasts also demonstrate great versatility when compared to other 
connective-tissue cells. These cells possess ‘a remarkable capacity to differentiate into 
other members of the family’ (Alberts et. al 2002). When tissues are damaged, 
fibroblasts become activated and differentiate into myofibroblasts which facilitate 
healing by producing ECM proteins and reducing the wound size by contracting local 
ECM. The proliferation of fibroblasts and their transition to myofibroblasts represent 
critical events in the process of wound healing and scarring (Li and Wang 2011). It is 
important to point out that the fibroblast differentiation into myofibroblast is 
dependent on transforming growth factor (TGF-β), an inflammatory cytokine with 
multiple cellular roles. TGF-β promotes the fibroblast-myofibroblast differentiation and 
plays a crucial role in many other regulatory processes including growth, proliferation, 
apoptosis and ECM production among others (Clark et al. 1998). The role of TGF-β in 
wound healing, abnormal scarring and fibrosis will be further discussed in sections 
1.2.5.1.4 -1.2.5.1.5 
1.2.5.1.3 The myofibroblast 
Myofibroblasts were initially described in 1971 in the granulation tissue of healing 
wounds (Gabbiani et al. 1971). They described the structure of these cells 
ultramicroscopically as a “modified fibroblast” with smooth muscle-like properties. 
From a morphological point of view, myofibroblasts are larger than activated fibroblasts 
(Dartt et al. 2010), and present ruffled membranes and a well-developed, active 
endoplasmic reticulum (Baum et al. 2011). They are characterised by highly organised, 
contractile bundles of actin microfilaments called stress fibres. The actin microfilaments 
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terminate in “fibronexus”, an adhesion complex which connects the myofibroblasts’ 
internal microfilaments to the surrounding extracellular matrix (Eyden 1993, Baum et al. 
2011). This creates a contractile mechanism capable of transmitting the force that is 
generated from stress fibres to the extracellular matrix. Similar to smooth muscle cells, 
myofibroblasts express α-smooth muscle actin (α-SMA) and incorporate it into 
intracellular stress fibres. α-SMA is generally accepted as the universal marker for the 
myofibroblast phenotype (Darby et al. 1990, Tomasek et al. 2002) unless smooth muscle 
is present. These cells mediate closure of wounds by virtue of their contraction and the 
formation of collagen-rich scars. However, their sustained presence in organs such as 
lungs, liver, and kidney beyond wound resolution, and continued matrix synthesis 
underpins progressive fibrotic disease. 
1.2.5.1.4 Myofibroblasts in the process of wound healing 
Early in the wound healing process, undifferentiated fibroblasts appear at the wound 
provisional matrix (Darby et al. 2007) and evolve to proto-myofibroblasts, which are 
transient cells involved in fibroblast to myofibroblast trans-differentiation (Desmoulière 
et al. 2005).   
Modulation from the fibroblast towards the proto-myofibroblast has been related to the 
accumulation of stress fibres and mechanical tension, while the switch from the proto-
myofibroblast to the differentiated myofibroblast is governed by TGF-β signalling, the 
presence of specialized ECM proteins (such as the cellular fibronectin (FN) splice variant 
ED-A) and further mechanical tension generated by the cell’s remodelling activities. Each 
of these factors alone cannot induce the myofibroblast phenotype and joint action is 
needed to stimulate the transition from proto-myofibroblast to myofibroblast (Tomasek 
et al. 2002, Chitturi et al. 2015).  
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The main difference between proto-myofibroblast and myofibroblast is the α-SMA in 
the latter (Tomasek et al. 2002) (Fig. 1.7). Myofibroblasts generate contractile forces 
due to the expression of α-SMA and play a crucial role in wound contraction and closure. 
The incorporation of α-SMA into stress fibres has been shown to significantly increase 
the contractile activity of myofibroblasts (Dugina et al. 2001, Hinz 2009). Several studies 
have shown that the TGF-β induces α-SMA expression (Desmoulière et al. 1993, Tamm 
et al. 1996). 
During the remodelling stage of normal wound healing, the synthesis of ECM is 
significantly diminished and the synthetic components suffer modifications until 
granulation tissue disappears completely (Darby et al. 2014). 
 
Figure 1.7 Stages of fibroblast to myofibroblast differentiation 
Under mechanical stress, fibroblasts acquire stress fibres and evolve to proto-myofibroblasts. 
The proto-myofibroblast phenotype is characterised by the presence of stress fibres, ECM 
proteins such as ED-A fibronectin and focal adhesions. In the presence of transforming growth 
factor β (TGF-β), and further mechanical tension, proto-myofibroblasts can form differentiated 
myofibroblasts. Myofibroblasts express α-smooth muscle actin (α-SMA). Adapted from Falke, 
Gholizadeh et al. (2015). 
 
Myofibroblasts typically resolve through a process called apoptosis (Darby et al. 1990, 
Desmoulière et al. 1995) once the wound proceeds to full epithelialisation, allowing 
resolution in the absence of an inflammatory response. However, predominantly in 
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pathological states, myofibroblasts fail to undergo apoptosis and their sustained 
presence is generally a marker of fibrosis and scarring (Meran et al. 2011, Darby et al. 
2014). Fibrotic diseases are responsible for about 45% of all deaths in the western world 
(Borthwick et al. 2013). Pathological cases resulting in fibrosis are generally 
characterised by the persistence and progression of highly synthetic myofibroblast cells. 
This persistence results in abnormal and excessive deposition of ECM which alters the 
normal structure of the tissue leading to excessive scarring and eventually to a complete 
loss of organ function. For example, Idiopathic Pulmonary Fibrosis (IPF) is a progressive 
and irreversible lung disorder that is characterised by a very poor prognosis. In 2012, 
this fibrotic disease played an etiological role in 0.9% of all deaths in the United Kingdom 
(British Lung Foundation- www.blf.org.uk) and the median survival time for IPF patients 
varies from 2 to 3 years after diagnosis (Raghu et al. 2011). This is because the condition 
is idiopathic and treatment alternatives are very limited. 
1.2.5.1.5 Role of myofibroblasts in fibrotic diseases (fibrosis and excessive scarring) 
Myofibroblast cells play a key role in abnormal wound healing and drive fibrotic diseases 
that affect several vital organs such as the kidney, lung, liver, and heart. Persistence of 
these cells is likely to depend on the local production of TGF-β (Webber et al. 2009). 
TGF-β not only induces the expression of α-SMA (Desmoulière et al. 1993, Hu, Wu et al. 
2003), but also stimulates the accumulation of the stress fibres that are needed to 
produce mechanical tension. TGF-β also increases the expression of FN (Ignotz et al. 
1986, Hocevar et al. 1999) and the focal adhesion complexes (Dugina et al. 2001, Wendt 
et al. 2009), which are important features of the myofibroblast phenotype (Chitturi et 
al. 2015). Furthermore, TGF-β alters the ECM production and contributes to the 
excessive accumulation of ECM proteins including collagens, fibronectin, proteoglycans 
and elastin by down-regulating matrix degrading enzymes and stimulating their 
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inhibitors (Leivonen et al. 2013). Early in the wound healing process, the balance 
between the proteinases that can degrade the matrix and their inhibitors favours ECM 
production. Later in the healing process, ECM starts a remodelling process and the 
balance changes, favouring apoptosis and matrix degradation (Lu et al. 2011). In 
pathological fibrosis, TGF-β stimulates the production of the matrix degrading inhibitors 
and contributes to the sustained presence of myofibroblast cells at the sites of injury. 
Therefore, TGF-β directly perpetuates the cycle of ECM deposition and impaired 
degradation that generally marks the progressive and irreversible remodelling seen in 
pathological fibrosis. Many studies suggest that future treatment approaches could 
consider the production of agents that would target and antagonise the activity of TGF-
β in fibrotic lesions (Funato et al. 1999, Fernandez et al. 2012). Results have shown that 
introducing neutralising antibodies to TGF-β in vitro considerably reduced the 
expression of α-SMA in the early stages of wound healing and stopped excessive ECM 
deposition (Shah et al. 1992, Yokozeki et al. 1997). However, TGF-β is a fundamental 
biological pathway and treatments targeted at TGF-β might be expected to carry 
significant toxicity risks (Gueorguieva et al. 2014). 
1.2.5.1.6 Metabolic reprogramming in myofibroblasts 
Metabolic reprogramming is an early and lasting event that takes place during 
myofibroblast differentiation (Xie et al. 2015) and plays a crucial role in the contractile 
function of the cell (Bernard et al. 2015). Myofibroblasts display augmented glycolysis 
during differentiation and some studies have suggested that TGF-β induces this process 
(Bernard 2015). The augmented glycolysis phenomenon in myofibroblasts is similar to 
the Warburg Effect (Warburg 1956) that occurs in cancer cells. It is widely accepted that 
cancer cells undergo metabolic programming and display augmented glycolysis to 
sustain proliferation. This phenomenon was extensively studied in cancer cells and 
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glycolysis is considered a therapeutic target for anticancer drugs (Hamanaka et al. 2012, 
Ganapathy-Kanniappan et al. 2013). However, the role of metabolic reprogramming in 
fibrotic diseases has not been fully explored yet. Glycolysis is a ten-step metabolic 
pathway in which one molecule of glucose is converted into two molecules of pyruvate. 
Then, under anaerobic conditions, lactate dehydrogenase (LDHA) converts pyruvate into 
lactate. Three reactions in the glycolytic pathway hexokinase (HK), phosphofructokinase 
(PFKM), and pyruvate kinase (PKM) enzymes, are irreversible and often considered rate-
limiting as they influence the overall glycolytic flux. It was reported that the enzymes 
catalysing these reactions are up-regulated during in vitro myofibroblast differentiation 
in IPF (Xie et al. 2015). The process of myofibroblast expansion involves two steps 
(differentiation and proliferation) which are closely related. In the presence of TGF-β, 
fibroblasts change phenotype and differentiate into myofibroblasts and then TGF-β is 
also reported to stimulate myofibroblast proliferation. Furthermore, augmented 
glycolysis is not only essential for myofibroblasts differentiation but might also be 
required for myofibroblast abnormal proliferation (Srivastava et al. 2018). 
Myofibroblasts produce ECM proteins that contribute to tissue repair and wound 
healing. Among these proteins, collagens are the major structural proteins and 
considered critical for the wound healing process. In the remodelling stage, collagen 
type III is gradually replaced by collagen type I (Darby et al. 2014). TGF-β stimulates 
collagen (type I) production (Chen et al. 1999, Petrov et al. 2002) and diminished 
collagen type III is associated with myofibroblast differentiation and formation of scars 
(Volk et al. 2011). One unique aspect of collagen is that glycine, a non-essential AA, 
accounts for about one third of the AAs in collagen molecule (Barbul 2008).   
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The de novo synthesis of the AA serine and its conversion to glycine (Fig. 1.8) represents 
an important metabolic pathway that plays an important role in protein, nucleic acids 
and lipids synthesis. Recently, this pathway was reported to play a crucial role in collagen 
formation in human lung fibroblasts of IPF (Nigdelioglu et al. 2016). Furthermore, TGF-
β was reported not only to stimulate glycolysis but also regulate the expression of genes 
involved in the biosynthetic pathway of serine and glycine (Nigdelioglu et al. 2016). De 
novo serine synthesis is derived from glucose via glycolysis, and glycolytic intermediate 
3-phosphoglycerate (3-PG) is converted to serine through a three-step enzymatic 
process involving phosphoglycerate dehydrogenase (PHGDH), phosphoserine 
aminotransferase (PSAT) and phosphoserine phosphatase (PSPH). Then, serine is linked 
to glycine metabolic pathway synthesis via serine hydroxymethyltransferase (SHMT). 
The detailed process is as follows: phosphoglycerate (3PG), a glycolytic intermediate, is 
firstly oxidized (using NAD+) in a reaction catalysed by phosphoglycerate dehydrogenase 
(PHGDH), to yield 3-phosphohydroxypyruvate. Then, 3-phosphohydroxypyruvate is 
transaminated into phosphoserine by phosphoserine aminotransferase (PSAT), using L-
glutamate and producing 2-oxoglutamate. Finally, phosphoserine is converted to serine 
by phosphoserine phosphatase (PSPH) using water and yielding phosphate. Then, 
glycine is formed from serine in a reversible reaction catalysed by serine 
hydroxymethyltransferase (SHMT). SHMT enzyme is present in both mitochondria and 
cytoplasm in the form of two isoenzymes SHMT1 and SHMT2. It was reported that in 
IPF, serine/glycine biosynthesis is required for collagen production and TGF-β 
upregulates the enzymes catalysing reactions in this biosynthetic pathway (Nigdelioglu 




Figure 1.8 Biosynthesis of serine and glycine 
Serine is synthesised from the glycolytic intermediate 3-PG. A set of 3 enzymes (PHGDH, PSAT, 
PSPH) catalyse the reactions constituting this pathway. Then, serine is converted to glycine via 
serine hydroxymethyltransferase (SHMT). Glycine is one of the main contributors to collagen 
synthesis, with about one third of collagen molecule being made up of glycine. 
 
A better understanding of the mechanism behind the myofibroblasts’ abnormal 
proliferation and collagen production is of paramount importance as it can provide 
insight into the causes for its sustained persistence and lead to additional targeted 
approaches to cure fibrosis and scarring. Thus, the work described here aims to 
reconstruct, analyse and compare the FBN and FBTGF models, while focusing on certain 
biological functions such as proliferation, glycolysis and collagen synthesis.  
1.2.5.2 Skeletal Muscle  
1.2.5.2.1 Skeletal muscle structure 
Muscle can be divided into three distinct types: skeletal, cardiac, and smooth. Each 
category of muscle tissue has a unique structure and performs different functions. 
Skeletal muscle is the only muscle tissue under voluntary control through nervous 
impulses from the cerebral cortex. The functions of skeletal muscle are to enable 
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movement, provide support and protection to the organs in the body. Skeletal muscle 
is directly attached to bones by tendons and is composed of long and cylindrical bundles 
of cells called muscle fibres that contain many nuclei. During development, fibres arise 
from the fusion of smaller cells (myoblasts) that retain their nuclei. For this reason, 
skeletal muscle fibre is very often referred to as a ‘post-mitotic, multinucleated muscle 
cell’. Myofibres contain an array of myofibrils that are organised in a region called the 
“sarcomere” that is the basic functional unit for contraction. Sarcomeres are composed 
of long protein filaments which allow the muscle cell to contract. These proteins include 
myosin, actin, and titin which are organised in thick filaments called myofilaments (Jones 
et al. 2004). Skeletal muscles are sometimes called striated muscles due to their 
distinctive appearance resulting from regularly arranged protein structures. Under the 
microscope, they present cross-striated striped pattern due to the distinct and regular 




Figure 1.9 An electron micrograph of skeletal muscle showing the interdigitating actin and 
myosin filaments which make up a sarcomere 
Adopted from Sprott et al. (2004) Copyright © 2004, BMJ Publishing Group Ltd. 
 
In each sarcomere, the thick filaments are comprised of myosin, while thin filaments are 
made up of actin. Thin and thick filaments interdigitate in the sarcomere to facilitate 
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muscle shortening and lengthening during contraction. The I band is the region of the 
sarcomere that contains thin actin filaments, while the A band contains thick myosin 
filaments (Jones et al. 2004). The thin and thick filaments overlap as thin filaments are 
extended into A band. However, the region in the A band where the thick filaments are 
not overlapped by the thin ones is called the H zone and contains myosin only (Cooper 
2000, Jones et al. 2004). The boundary region of each sacromere is called the Z disc (or 
Z line) and the middle region in the sarcomere (between two Z lines) forms the M line 
(Fig. 1.10). Neighbouring sarcomeres share the same Z lines (Cooper 2000). When 
contraction occurs, the Z lines come closer together and sarcomere shortens. The width 
of the A band remains constant, I band becomes shorter and H band no longer appears 
(Cooper 2000, Jones et al. 2004).  
 
 
Figure 1.10 Sarcomere structure 
The I band contains thin filaments made of actin, while the A band contains both actin and 
myosin filaments. The region in the A band where thick and thin filaments are not overlapped is 
called the H zone and consists of myosin only. Each sarcomere is bordered by two Z lines. The M 





The sarcomere contains some additional proteins such as titin, nebulin, troponin and 
tropomyosin. Titin and nebulin are the largest in the sarcomere region and contribute 
to the sarcomere’s structure and stability (Wang 1996, Ottenheijm et al. 2012). Muscle 
activation and control at the cellular level is through the thin filament complex 
comprising actin, troponin and tropomyosin. Troponin is itself a complex of three 
proteins (troponin C, troponin I and troponin T) coupled to tropomyosin. Troponin 
serves as a calcium regulator for skeletal muscle contraction (Gomes et al. 2002). The 
binding of calcium to troponin causes the unwinding of tropomyosin which reveals 
binding sites on actin to which the cross-bridges from the myosin filament can attach 
and produce force and movement (C. El-Saleh et al. 1986). The ATP is hydrolysed into 
adenosine diphosphate (ADP) and phosphate, producing energy that is transferred to 
the heads of myosin filaments. This energy is used by the myosin to pull the actin 
filaments toward each other from both sides, shortening the sarcomere and producing 
contraction. When a new ATP molecule binds to myosin, the myosin and actin separate 
from each other and the cross-bridge detaches (Jones, Round et al. 2004). This process 
is repeated many times as long as there is sufficient calcium present with ATP, the fuel 
for contraction being recharged through various metabolic pathways. As there is only 
about two seconds worth of ATP in a cell, there are a series of processes by which ATP 
can be generated for the maintenance of contraction which depend on intensity and 
duration of exercise, balancing the requirements of metabolic power (rate of ATP 
generation) with capacity (amount of fuel store). These are through substrate level 
phosphorylation (phosphocreatine (PCr) degradation and glycolysis) and oxidative 
phosphorylation of carbohydrates and fats during aerobic exercise.  
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1.2.5.2.2 Skeletal muscle regeneration and growth 
Skeletal muscle cell is a post-mitotic cell which means that the repair and regeneration 
of the skeletal muscle tissue is dependent on the stem-like satellite cells which are 
located between the basal lamina and plasma membrane of muscle fibres. Whenever 
mechanical strain occurs, these cells become activated and facilitate repair and 
regeneration of the muscle tissue. It was reported that satellite cells play a crucial role 
not only in the muscle regeneration and repair but also in the muscle growth (Phillips 
2014, Bazgir 2017). Since muscle fibres are unable to produce nuclei, satellite cells 
participate in muscle growth by donating myonuclei to existing muscle fibres (Blaauw et 
al. 2014). 
The number of muscle cells is mainly defined in the pre-natal and early postnatal period 
after which muscle growth occurs by an increase in the size of existing fibres - their 
diameter or cross-sectional area, a process known as “hypertrophy”. The opposite 
process is called atrophy and is characterised by a decrease in the muscle mass. Muscle 
atrophy can occur in health with unloading (such as limb immobilisation, bed rest or 
microgravity) or in disease such as cachexia (with cancer or HIV) and with ageing 
(sarcopenia). Muscle growth can also occur when stretch is imposed and the length of a 
muscle is increased through the addition of sarcomeres in series (Williams et al. 1971). 
The sarcomere is well-conserved throughout evolution and biology. Although the 
number of muscle fibres may differ among different species, sarcomeres in humans and 
animals share the same essential properties, the only difference being the number of 
sarcomeres that add up in series or in parallel. The architectural design of the muscle 
has an impact on its functional properties (Lieber et al. 2011). For instance, the way 
sarcomeres are added up has an effect on the force and velocity of contraction. 
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Sarcomeres added up in series would mean a faster velocity while those added up in 
parallel would produce an increased force during contraction (Fig. 1.11). 
In the adult, the response to mechanical overload (e.g. resistance exercise) and feeding 
results in hypertrophy. Here contractile proteins accumulate as the protein synthesis 
rate exceeds the protein breakdown rate (Tipton et al. 2001). In humans, growth is 
driven by an increased protein synthesis rather than a reduction in rate of muscle 
protein breakdown (Carraro et al. 1990). AAs are required to build the proteins and the 
provision of AAs is reported to be the major stimulant for an increased protein synthesis 
(Atherton et al. 2012). During hypertrophy there is an increase in actin and myosin 
filaments within each sarcomere (myofibrillar protein synthesis) and this leads to an 
increase of the entire contractile unit which is formed by myosin, actin, troponin and 
tropomyosin. This unit constitutes about 80% of the entire muscle fibre (Wilborn et al. 
2004). The most abundant contractile protein is myosin which represents about 25% 
total muscle protein (Wilborn et al. 2004) while actin represents 10% of the total muscle 
protein (Cooper 2000). These two proteins are the major components of the contractile 








Figure 1.11 Sarcomeres in series vs. sarcomeres in parallel 
The force-velocity curves of two hypothetical muscles (A, B) were plotted. A has a high number 
of sarcomeres in parallel giving high force and low velocity, while B has a low number of 
sarcomeres in series giving high velocity and low force. 
 
 
1.2.5.2.3 Hypoxia, protein synthesis and muscle atrophy 
Hypoxia can be defined as a deprivation of the amount of oxygen in the whole body or 
in some tissues. Hypoxia occurs during ascent to high altitude such as climbing a 
mountain where the oxygen partial pressure (tension) is lowered. Clinically, hypoxia 
occurs in patients with lung diseases such COPD or lung fibrosis, despite them having 
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sufficient ambient oxygen. Hence the need for oxygen supplementation in some 
patients with severe breathing difficulties. Furthermore, tissue hypoxia can also occur in 
ischaemia when there is insufficient blood flow to maintain tissue viability/normal 
function. 
Hypoxia has been reported to impact body weight (Boyer et al. 1984, Rose et al. 1988), 
muscle size (Hoppeler et al. 1990) at high altitude and in vitro studies suggest that 
muscle atrophy in hypoxia may be attributed to a reduction in protein turnover 
(Kraggerud et al. 1995). Although hypoxia has been associated with muscle atrophy at 
high altitude, its impact on the protein synthesis and AA provision in skeletal muscle has 
not been fully understood and results remain controversial (Pasiakos et al. 2017). For 
instance, a lot of additional factors such as diet, amount of sleep and physical activity 
can impact protein balance and muscle mass during hypoxia exposure at high altitudes. 
Hypoxia at high altitudes is reported to reduce appetite and perturb the sleep cycle, 
factors that can impact protein turnover rate. These factors must also be considered 
when analysing the impact of hypoxia at high altitude (Kucharzewska et al. 2015).  
The main mechanisms for ATP synthesis are oxidative phosphorylation and glycolysis. 
Oxidative phosphorylation, which takes place in mitochondria, is the principal energy 
provider of the cell and only a small amount of ATP is produced through glycolysis (Fig. 
1.12). During hypoxia the amount of mitochondrial ATP is reduced. In consequence, the 
amount of ATP required for protein synthesis is reduced too and anaerobic glycolysis 
cannot fully compensate for this loss. It has been reported that in low oxygen 
environment, skeletal muscle undergoes metabolic reprogramming by favouring 
anaerobic glycolysis over mitochondrial metabolism (Chicco et al. 2018). This process 
was initially described by Louis Pasteur in 1857 and is also known as “Pasteur Effect” 
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(Dixon et al. 1935). This metabolic switch that happens in low oxygen conditions is 
reported to involve HIF-1 (hypoxia inducible factor 1) which regulates several glycolytic 
enzymes and inhibits pyruvate dehydrogenase which converts pyruvate to acetyl-CoA 
(Kim et al. 2006).  
 
 
Figure 1.12 A brief overview of the key components of cellular respiration 
Glycolysis converts glucose to pyruvate, a process that produces a small amount of ATP and 
NADH (anaerobic respiration). In aerobic respiration, when oxygen is present, pyruvate formed 
in glycolysis is converted to acetyl-CoA which enters in the TCA cycle. In the TCA cycle, acetyl-CoA 
is oxidised and the released electrons and hydrogen atoms combine with NAD+ and FAD+ to form 
NADH and FADH2. The electron carriers (NADH and FADH2) donate electrons to the electron 
transport chain, which leads to the phosphorylation of ADP, resulting in ATP. 
 
1.2.5.2.4 AA supplementation 
The AAs are the building blocks of the proteins. Nine of them (histidine, isoleucine, 
leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) are 
considered essential amino acids (EAA). This means that these AAs cannot be produced 
by the body and need to be supplied through diet. The other AAs can be synthesised by 
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the organism. Protein synthesis in the skeletal muscle is dependent on AA availability 
and each of the AAs, both essential and non-essential, must be provided in the right 
amounts. Three of the EAAs (isoleucine, leucine and valine) are known as branched-
chain amino acids (BCAA) due to their unique structure with side chains containing a 
central carbon. It was reported that with these AAs, muscles are able to increase protein 
synthesis rate and stimulate muscle growth (Blomstrand et al. 2006). Furthermore, 
leucine alone, was reported to play a crucial role in regulating protein synthesis by 
activating the mTOR (mammalian target of rapamycin) signalling pathway to produce an 
anabolic response (Garlick 2005, Norton et al. 2006). The anabolic response represents 
the state in which protein turnover is positive, i.e. protein synthesis rate exceeds the 
protein degradation rate (Wolfe 2017). Despite what has been reported about leucine, 
most commercially available protein supplements comprise a mixture of AAs. The 
hypothesis that some combinations of AAs may augment protein synthesis rate gave rise 
to a large industry. For instance, a report published by Zion Market Research predicted 
that global dietary supplements market will be worth 220.3 billion USD by 2022 (Zion 
Market Research, 2015). However, the results of the scientific reports focusing on AA 
supplementation remain controversial.  
In summary, this literature review has set the background for the modelling approach 
to be used and described the rationale for the cell types to which the modelling work is 
to be applied. The specific aims of the work presented in this thesis are thus to: 
• Construct two genome-scale metabolic models for the normal fibroblast 
(control) and TGF-β-stimulated fibroblast (myofibroblast). 
• Use constraint-based approaches to study these cells in regard to proliferation, 
glycolysis and collagen synthesis. 
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• Construct a genome-scale metabolic model for the skeletal muscle cell. 
• Use constraint-based methods to investigate the effects of hypoxia and amino 
acid supplementation on skeletal muscle metabolism, focusing on protein 






















Chapter 2: Materials and methods 
This chapter will present the methods used to reconstruct and analyse the CBMs of 
normal fibroblasts (FBN), TGF-β-stimulated fibroblasts (FBTGF) or myofibroblasts and 
skeletal muscle cell. In addition to a description of the computational methods, this 
chapter will also consider RNA-sequencing (RNA-seq) data sources used in the 
reconstruction process and the experimental procedures that were used to derive these 
data.  
2.1 Experimental methods 
2.1.1 Transcriptomics data 
Transcriptomics is the study of the transcriptome, or the set of RNA molecules that are 
produced by a genome in a cell or tissue. RNA sequencing (RNA-seq) and microarrays 
are the most common choices for studying the transcriptome in an organism. RNA-seq 
analysis, also known as whole transcriptome shotgun sequencing (WTSS), uses deep 
sequencing technologies for transcriptome profiling. RNA-seq has a number of 
advantages over microarrays (Wang et al. 2009). Unlike arrays, RNA-seq does not 
depend on the availability of probes that cover already known genes and can detect 
novel and rare transcripts, as well as splice variants. That is why RNA-seq is more 
effective in discovery-based studies (Wang et al. 2009). RNA-seq also avoids the 
hybridization-based issues (background noise, saturation etc) which are usually 
associated with microarrays. Thus, RNA-seq is more efficient in detecting genes with low 
expression compared to microarrays (Zhao et al. 2014). 
2.1.2 RNA sequencing  
RNA-seq was performed by the Centre for Inflammation and Tissue Repair, University 
College of London (UCL). To obtain these data, confluent monolayers of human primary 
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lung fibroblasts from healthy volunteers were stimulated (control) with 1ng/ml of TGF-
β1 (porcine origin, R&D Systems, USA) for 24 hours using standard Dulbecco's Modified 
Eagle Medium (DMEM). Total RNA extraction was performed using miRCURY RNA 
Isolation Kit (Exiqon, Denmark). Poly(A)-tailed RNA enrichment and library preparation 
were performed using the KAPA Stranded mRNA-Seq Kit with KAPA mRNA Capture 
Beads (KAPA Biosystems, Wilmington, MA, USA). Data were stranded and paired-end 
sequenced to a depth of 15M using NextSeq (Illumina, San Diego, CA, USA). Reads were 
pre-processed and aligned to the reference genome (Homo sapiens UCSC hg19) using 
STAR aligner (Selvarajah et al. 2019). 
2.2 Computational methods 
2.2.1 Programs and software packages  
R (R Core Team 2013) is a free and open source programming language that is used for 
statistical computing, graphics, data analysis and data visualisation. R was used to 
process and manipulate gene expression data. BiomaRt (Durinck et al. 2009) is a 
Bioconductor (www.bioconductor.org) package that provides an R interface to several 
public biological databases such as Ensembl (Hunt et al. 2018), COSMIC (Tate et al. 
2018), UniProt (Consortium 2018), HGNC (Yates et al. 2017), Gramene (Tello-Ruiz et al. 
2018) or WormBase (Harris et al. 2019). In this thesis, BiomaRt was used to convert 
Ensembl gene IDs to HUGO gene IDs. Custom Python scripts were used to perform data 
manipulation tasks such as counting the occurrence of an object in list or joining data 
sets. DeSeq2 (Love et al. 2014), another Bioconductor package, was used for the 
normalisation and log2 transformation of the gene expression values and to perform 
differential gene expression analysis. MATLAB (The MathWorks, Natick, MA, USA) is a 
high-level programming language that can be used for algorithm implementation and 
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numerical computation. It is used for solving linear algebra problems and has a rich set 
of matrix and array operations. MATLAB was used as the principal programming 
language to build CBMs and run simulations. COBRA Toolbox (Becker et al. 2007) is a 
software package which contains several comprehensive MATLAB scripts useful for 
constraint-based modelling. These scripts can be used to build and analyse metabolic 
networks using constraint-based methods. In this thesis, the COBRA Toolbox was used 
to construct, validate and simulate three genome-scale models for the FBN, FBTGF and 
skeletal muscle cell. CPLEX (IBM ILOG CPLEX) is a high-performance linear programming 
solver that can deal with Linear Programming (LP), Mixed Integer Programming (MIP) 
and Quadratic Programming (QP) problems. CPLEX was used to solve LP problems that 
are part of the FASTCORE family of algorithms and for the optimisation of several 
objective functions of the model. 
2.2.2  Differential expression analysis 
Differential expression analysis (DEA) performs statistical analysis to verify whether a 
gene’s expression varies between two or more conditions based on the normalised 
expression data from a small number of replicates. In this framework, DEA was 
performed using the Deseq 2 package in R to analyse the expression of the genes in the 
“control” and “TGF-β-stimulated” conditions. Four replicates were used for each 
condition. 
Deseq 2 models the raw count data by first estimating the size factors to account for the 
library depth. Next, the gene-wise dispersions are estimated, and a curve is fitted to 
these estimates. To produce more accurate results, the gene-wise dispersion estimates 
are corrected using the average expression strength over all samples. It is important to 
point out that Deseq 2 assumes that genes of similar average expression levels have 
similar dispersion. Next, Deseq 2 fits a negative binomial general linear model (GLM) 
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that produces the final log2 fold change. Finally, the fold changes are shrunk according 
to the mean and dispersion of a gene. Thus, genes with very low counts are shrunk 
towards zero. Finally, the hypothesis testing is performed using the Wald-test with the 
null hypothesis stating that there is no significant difference between the average 
expression levels of the two conditions for a certain gene. Thus, the p and p-adjusted 
values are obtained for every gene.  
RNA-seq data was loaded in R and the Ensembl gene ids were converted to the 
corresponding HUGO gene symbols. After the successful implementation of the Deseq2 
protocol (Love et al. 2014), a table containing gene names (as row names) together with 
the corresponding p-value, p-adjusted value and log2 fold-change value was obtained. 
Firstly, genes were sorted in ascending order by the p-adjusted value to identify those 
genes with the most significant fold-change. Then, a volcano plot was used to analyse 
the results from the DEA. A volcano plot is a type of scatter plot that displays “fold-
change” versus “significance”. In this way, one can plot the genes with the largest fold 
changes which are also most statistically significant. In a volcano plot, the X-axis shows 
the log2 fold-change value, while the Y-axis represents negative log10 of the p-value. 
Genes of particular interest for the analysis of the models were displayed on the volcano 
plot to investigate whether they were up-regulated or down-regulated under TGF-β 
stimulation. The results of DEA are described in section 3.3.5 from Chapter 3. 
2.2.3 Processing RNA-seq data for model generation 
Data sets generated from RNA-seq analysis were loaded into MATLAB. Entrez genes 
were mapped to the equivalent HUGO Gene ID used in Recon2.2. MATLAB and HGNC 
data set (HUGO Gene Nomenclature Committee at the European Bioinformatics 
Institute) were used in this step. Recon 2.2 (Swainston et al. 2016) was used as a basis 
for generating a genome-scale model. Recon 2.2 consists of 1673 genes, 7785 reactions 
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and 5324 metabolites. The GPR associations in Recon 2.2 were used to identify active 
(core) reactions in the required biological context and FASTCORMICS (Pacheco et al. 
2015), an adaptation of FASTCORE algorithm (Vlassis et al. 2014), was used to generate 
context-specific models.  
2.2.4 FASTCORE  
FASTCORE is a family of algorithms that can be used to generate context-specific models. 
The FASTCORE family is comprised of FASTCORE (Vlassis et al. 2014) and three other 
algorithms: FASTCORMICS (Pacheco et al. 2015), FASTCC (Pacheco et al. 2015) and 
fastgapfill (Thiele et al. 2014). FASTCORE considers a core set of reactions that have 
strong evidence to be active in a certain biological context and then adds a minimum set 
of reactions from the global network to the initial core set in order to create a context-
specific model. For instance, this problem can be summarized as follows: Given a global 
network with 𝑨𝑨 reactions and stoichiometric matrix SA and a set B⊆A, find the smallest 
possible set C ⊆ A such that B⊆C and all reactions in the subnetwork (Sc, C) can carry a 
non-zero flux in at least one flux distribution (network consistency). Thus, the algorithm 
considers a core set of reactions 𝑱𝑱 ⊆ 𝑩𝑩 with high confidence of being active and a 
penalty set 𝑷𝑷 = (𝑨𝑨\𝑩𝑩)\𝑪𝑪 formed of non-core reactions. At every step, the algorithm 
solves two LP problems: one for the maximisation of the flux through as many core 
reactions as possible (LP 2.1), and another one for the minimisation of the flux through 
reactions which are not included in the core (LP 2.2).   
It is worth mentioning that FASTCORE aims to include in the reference network all 
reactions that belong to the core set (Vlassis et al. 2014). Thus, FASTCC checks the 
consistency of the network and identifies flux-inconsistent reactions. In this framework, 
network consistency is valid when every reaction has a flux of at least ε. The value for ε 
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can be varied and it often depends on the magnitude of the uptake/secretion rates in 
the model. Investigating the consistency of a network is a commonly used method the 
identification of potential flaws and deficiencies in a metabolic network (Acuña et al. 
2009). FASTCC is a variant of FASTCORE which considers all reactions in the network to 
be part of the core set and has no penalty set. If the network is not consistent, FASTCC 
provides a list of flux-inconsistent (blocked) reactions. FASTCC is comprised of the 
following major steps:   
• Step 1: Consider all reactions in the core by default and maximises flux through 
as many core reactions as possible.  
• Step 2: Take all reactions in the core set that carry a flux greater than or equal to 
a threshold ε and force them to carry flux, while minimising the overall flux in 
the network.  
•  Step 3: Reactions that could carry flux in step 2 are added to the model and 
removed from the core. Irreversible reactions that couldn’t carry flux are 
identified and considered blocked reactions.  
• Step 4: For each remaining reversible core reaction: Reverse the directionality of 
the reaction (flip) and test whether it can carry flux. If the reaction is carrying 
flux, remove it from the core set and add it to the model. Reactions that are still 
unable to carry flux are considered blocked reactions. 





𝑆𝑆𝑣𝑣 = 0 
𝑠𝑠𝑡𝑡 𝑠𝑠ℎ𝑎𝑎𝑠𝑠 𝑚𝑚𝑖𝑖 ∈ [0, 𝜀𝜀] 𝑓𝑓𝑡𝑡𝑜𝑜 𝑎𝑎𝑛𝑛𝑎𝑎 𝑖𝑖 ∈ 𝐽𝐽 and a small positive threshold 𝜀𝜀 
𝑣𝑣𝑖𝑖 ≥ 𝑚𝑚𝑖𝑖 𝑓𝑓𝑡𝑡r 𝑎𝑎𝑛𝑛𝑎𝑎 𝑖𝑖 ∈ 𝐽𝐽  
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𝑙𝑙𝑖𝑖≤𝑣𝑣𝑖𝑖≤𝑢𝑢𝑖𝑖 (𝐿𝐿𝐿𝐿 2.1) 
Where 𝑱𝑱 is a subset of B (core set) and 𝑙𝑙𝑖𝑖 ,𝑢𝑢𝑖𝑖 represent the lower and upper flux bounds.  
This LP problem is sufficient to assess the irreversible reactions and identify the blocked 
ones. However, it works only for positive fluxes. For negative fluxes, an iterative 
approach is taken. Reversible reactions are assessed one by one using LP 2.1, in both 
directions and this is achieved by flipping signs of elements in the columns of the 
stoichiometric matrix. It is important to point out that LP 2.1 is the same as the first LP 
problem solved by FASTCORE at every step. The second LP problem (LP 2.2) aims to 
minimise the L1 norm of vector 𝑣𝑣𝑖𝑖 ( ∑ |𝑣𝑣𝑖𝑖 |𝑖𝑖∈𝑃𝑃  ) in the penalty set 𝐿𝐿 = (𝐴𝐴\𝐵𝐵)\𝐶𝐶 subject 
to a minimum flux for the active reactions in new subset 𝐾𝐾 ⊆ 𝐽𝐽. 𝐾𝐾 is obtained after a 
single run of LP 2.1. The mathematical formulations of LP 2.1 and LP 2.2 were adapted 





𝑆𝑆𝐴𝐴𝑣𝑣 = 0 
 𝑠𝑠𝑡𝑡 𝑠𝑠ℎ𝑎𝑎𝑠𝑠 𝑣𝑣𝑖𝑖 ∈ [−𝑚𝑚𝑖𝑖 , 𝑚𝑚𝑖𝑖] 𝑓𝑓𝑡𝑡𝑜𝑜 𝑎𝑎𝑛𝑛𝑎𝑎 i ∈ 𝐿𝐿  
𝑣𝑣𝑖𝑖 ≥ 𝜀𝜀 𝑓𝑓𝑡𝑡r 𝑎𝑎𝑛𝑛𝑎𝑎 𝑓𝑓𝑡𝑡𝑜𝑜 𝑎𝑎𝑛𝑛𝑎𝑎 𝑖𝑖 ∈ 𝐾𝐾  
𝑚𝑚𝑖𝑖 > 0  
𝑙𝑙𝑖𝑖≤𝑣𝑣𝑖𝑖≤𝑢𝑢𝑖𝑖 (𝐿𝐿𝐿𝐿 2.2)  
Fastgapfill (Thiele et al. 2014) is an algorithm that uses FASTCORE concepts and aims to 
identify and fill potential gaps in the genome-scale metabolic model. Fastgapfill uses the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa et al. 2000) as a 
reference network in this process. Firstly, fastgapfill identifies blocked reactions and 
dead-end metabolites based on the reference network, and then fills the gaps with 
metabolic, exchange and transport reactions that will connect dead-end metabolites 
62 
 
and restore network consistency. It is important to point out that one can prioritise the 
type of reaction that should be added. In general, the desired order is metabolic over 
exchange and transport reactions.  
In order to map gene expression data to GPRs in the global reconstruction network, fixed 
thresholds are commonly imposed to distinguish between active and inactive genes. 
FASTCORMICS (Pacheco et al. 2015) is an adaptation of FASTCORE that uses Barcode 
(McCall et al. 2011) as a discreditation tool. Expression data is converted into z-scores 
(the number of standard deviations) using Barcode and then compared to a 
recommended threshold of 5z. Also, FASTCORMICS introduces an unexpressed 
threshold of 0 (standard deviation). This prevents the inclusion of reactions regulated 
by unexpressed genes. Those genes with 90% of arrays greater than 5z are assigned 1, 
while those with 90% arrays lower than unexpressed threshold (0) are assigned -1. 
Genes with a score of 1 are included in the core set while those with a score -1 are 
removed from the model. Then, a slightly different version of FASTCORE is run to 
maximise flux through core reactions and penalise the non-core ones. Unlike traditional 
FASTCORE, this modified version also allows for a set of not-penalised reactions. By 
heuristics, transport reactions are removed from the core, included in the non-penalty 
set and favoured over non-core ones. The reason for this is because transport reactions 
are usually regulated by promiscuous genes that control many other reactions. 
Furthermore, one can add reactions of interest in the core set and force them to carry 
flux. This set of “forced” core reactions is known as essential reactions set. This set is 
manually defined by the user and is comprised of those reactions which were removed 
by FASTCORE but were reported in the literature to be present, or reactions that were 
recently added to the model (e.g. biomass reaction, collagen synthesis, etc.), which one 
wants to make sure are picked by FASTCORE in the final model output. After this is done, 
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FASTCORE is run once with all essential reactions (the set defined by the user, not the 
core set determined by the algorithm). Then, the reactions in the "to remove" set are 
removed, and FASTCC is run on the remaining model. If any reaction from the essential 
reactions set cannot carry flux anymore, all reactions from the previous solution above 
are re-added. All core reactions, which are no longer in the consistent model are then 
removed from the core. The assumption is that reactions from the essential reactions 
set are prioritised over the active ones. Finally, in the last step FASTCORE is run with the 
remaining core reactions, while not punishing flux through the non-penalty set. 
2.2.5 Initial model generation 
Barcode was initially designed for microarray data. Thus, FASTCORMICS was adapted 
with a different pre-processing step to determine the active and inactive reactions in 
the context-specific model. For the FBN and FBTGF data, gene expression values (counts) 
were normalised using the R package DeSeq2, then log2 transformed with an offset of 
1, and genes with count > 1 were called present and assigned 1, while all other genes 
were called absent and assigned -1. Essentially, corresponding reactions to absent genes 
(-1) were evaluated as inactive and then placed in the "to remove" set. Similarly, the 
active genes (1), were used to determine active reactions and placed into the core set. 
For the skeletal muscle data, the same discreditation process was applied for the 
transcripts per million (TPM). A cut-off value of 1 was chosen based on sensitivity 
analysis for all three data sets: FBN, FBTGF and skeletal muscle (Fig. 2.1). Sensitivity 
analysis is a mathematical method to assess the robustness of a model or system with 

















































Figure 2.1 (a) (b) (c) The relationship between cut-off value and the number of reactions in the 
model 
The cut-off value was varied between 0.1 and 12 and for each cut-off value (either counts or 
transcripts per million), the number of reactions was determined. After 1 there is a relatively 
steady decline in the number of reactions (1 becomes an inflexion point). Thus, a cut-off value of 
1 was chosen and all genes with expression below 1 (between 0 and 1) were removed from the 
model.  
 
2.2.6 Manual refinement 
Despite the improvement in automated reconstruction methods it is widely accepted 
that manual refinement is still needed (Thiele et al. 2010). Thus, the model was manually 
inspected, curated and refined with the aid of literature data. FASTCORE is a very 
“restrictive” algorithm and only allows reactions which are necessary for the use of the 
core to stay in the model. This is in some ways a drawback of FASTCORE as this algorithm 
tries to generate minimal networks so if some exchanges are not part of the core set, 
they are likely to be removed. One idea of FASTCORE is to not add unnecessary reactions 
and rather generate a small model of highly active metabolism. Thus, missing reactions 
(mainly exchange ones) were added either manually or by using the essential reaction 
set that forces missing reactions to carry flux. Next, FASTCC was run to identify flux 
inconsistent reactions. Finally, flux inconsistent reactions were removed from the model 
(Fig. 2.2). Furthermore, several constraints were imposed on exchange reactions to 




















values and are further detailed in sections 3.2.1 and 4.2.2. Tables 6.2.1-6.2.3 in the 




Figure 2.2 Model generation process and manual refinement 
The curation process starts with the definition of the essential reaction set which forces certain 
reaction to become part of the “core” set. Next, the curation process continues with the manual 
addition of certain reactions. Finally, FASTCC is run for the last time to remove the flux 
inconsistent reactions which might be generated by the manual addition of certain reactions. 
 
2.2.7 Model analysis 
2.2.7.1 Flux balance analysis 
FBA (Orth et al. 2010) was used to find flux distributions that optimise certain objective 
functions in the model. However, FBA provides a single solution for the optimisation 
problem and alternate possible solutions should be assessed.  
2.2.7.2 Flux variability analysis 
FVA (Mahadevan et al. 2003) was employed to calculate the maximum and minimum 
flux range in the steady-state feasible solution space. FVA allows for the same objective 
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function and constraints as for FBA optimisation. Essential reactions were identified 
using flux spans. Flux spans were derived using the absolute difference between 
maximum and minimum fluxes generated by FVA. Then relative flux spans were 
calculated and expressed as ratios. Flux span ratios were defined as the absolute value 
of the difference between maximum and minimum flux generated by FVA, divided by 
the absolute value of the FBA flux. These ratios were sorted in ascending order and those 
reactions with the lowest flux span ratio were considered essential to the objective 
function (reaction). It is important to point out that this method is not able to put 
reactions into categories (essential or not essential). However, the ascending sort order 
of flux span ratios can suggest which reactions are most “sensitive” to a certain objective 
function. Not surprisingly, exchange and transport reactions for AAs, water, oxygen, etc. 
feature heavily in any list of essential metabolic reactions. Those reactions were 
excluded from the list as their essentiality to a certain objective function is expected. 
2.2.7.3 Gene essentiality analysis 
FBA-based GEA (Edwards et al. 2000) was used to identify essential genes for the 
required objective functions. Essential genes were defined as those genes the deletion 
of which will significantly impact the objective function. In this framework, essential 
genes were defined as those genes whose deletion would completely disable an 
objective function (generate a zero FBA flux). GEA can identify single essential genes 
(single gene deletion) or pairs of essential genes (double gene deletion). Critical genes 
were defined as those genes whose deletion will considerably reduce the flux for the 
objective function. 
2.2.7.4 Robustness analysis 
Robustness analysis (Edwards et al. 2000) was used to investigate and visualise how 
changes in the uptake rates of a certain reaction impact the objective function. 
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2.2.8 Objective functions  
Optimisation requires an objective function. Three objective functions, simulating 
reactions which are central to the modelling objectives, were constructed. They are 
biomass production, collagen synthesis and myofibrillar protein synthesis (production 
of Acto-Myosin complexes). 
2.2.8.1 Biomass reaction 
During proliferation, cells modify their metabolism to meet the requirements of this 
biological function and support macromolecule and precursor synthesis. Biomass rates 
are usually tightly coupled to proliferation rates (Vaidyanathan et al. 2006) and 
metabolic processes behind biomass objective function are closely related to cell 
proliferation (Fajas et al. 2018). Optimising a biomass reaction can provide an insight 
into the cells’ metabolic circuits during proliferation. 
To build a biomass reaction for the two models, the macromolecular content of the 
fibroblasts was derived from the relevant literature (weight fraction of protein, lipids,  
sugar, RNA and DNA): protein (Galacci and Higuchi, 1966), lipids (Macarak et al. 1979, 
Harzer et al. 2001), sugar (Umapathysivam et al. 2005), RNA (Miltenyi Biotec GmbH, 
2009) and DNA (Bordbar et al. 2010). The macromolecular weight percent contribution 
of each constituent was calculated using well-accepted methods (Bordbar et al. 2010). 
Biomass calculations in Bordbar et al. (2010) were used as a template for our 
calculations. Then, each macromolecule was broken down into smaller building blocks 
or components that are required to synthesise the macromolecule in terms of molar 
fractions. Thus, lipids were broken down in two fractions of the total lipids: neutral lipids 
and phospholipids. Neutral lipids were broken down into individual fatty acids that are 
present in the chemical processes from the cell metabolic network. The molecular 
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weight for every fatty acid was calculated and incorporated in the biomass reaction. 
Sterols, triglycerides and diglycerides were also included in the biomass composition.  
Major phospholipids (phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, 
phosphatidylserine/phosphatidylinositol, phosphatidylglycerol, lyso(bis)phosphatidic 
acid) were considered and their contribution to the biomass reaction was calculated. 
Also, proteins were broken down into AAs and considered in the biomass formulation. 
Glycogen was considered the main source of sugars. ATP maintenance requirements, 
proportion of DNA and RNA monomers were also calculated and incorporated in the 
biomass reaction.  All calculations for the biomass reaction are further detailed in Tables 
6.1.1-6.1.7 in the Appendices. The literature sources are included in the table. It is 
important to note that when no human fibroblast data was available, rat/chicken 
fibroblast data was used to fill the gaps. Human reconstruction (Recon 1) was previously 
used to generate a genome-wide model for mouse metabolism with excellent predictive 
capabilities. Furthermore, it was reported that human physiology is more related to 
farm animals than to rodents (Hamernik 2019) and chicken provides a suitable model 
for the study of human metabolism or disease (Schock et al. 2016, Hamernik 2019). 
Finally, human macrophage data (Bordbar et al. 2010) was considered when no 
fibroblast parameters of any kind were found.  
2.2.8.2 Collagen synthesis 
A collagen production reaction was added to Recon 2.2. The AA sequence for collagen 
(type I) was obtained from UniProt (www.uniprot.org). Every letter in the sequence 
accounts for an AA. The occurrence of every letter was counted using the Python 
programming language and the total counts were incorporated in the collagen reaction 
as stoichiometric coefficients for the corresponding AAs. Energy requirements were 
adapted from a biochemistry problem proposed in (Berg et al. 2002)). In this problem it 
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was assumed that the hydrolysis of inorganic phosphate (PPi) is equivalent to the 
hydrolysis of ATP, i.e. 𝐴𝐴𝐴𝐴𝐿𝐿 →  𝐴𝐴𝑀𝑀𝐿𝐿 + 𝐿𝐿𝐿𝐿𝑖𝑖  and 𝐿𝐿𝐿𝐿𝑖𝑖 →  𝐿𝐿𝑖𝑖 provides the same energy. 
Thus 𝐴𝐴𝐴𝐴𝐿𝐿 →  𝐴𝐴𝑀𝑀𝐿𝐿 + 2𝐿𝐿𝑖𝑖 gives double the energy as 𝐴𝐴𝐴𝐴𝐿𝐿 →  𝐴𝐴𝑀𝑀𝐿𝐿 + 𝐿𝐿𝐿𝐿𝑖𝑖. The same 
principle applies for 𝐺𝐺𝐴𝐴𝐿𝐿 →  𝐺𝐺𝑀𝑀𝐿𝐿 + 2𝐿𝐿𝑖𝑖. Thus, to combine 𝑛𝑛 AAs, the energy equivalent 
of 2𝑛𝑛 𝑚𝑚 (𝐴𝐴𝐴𝐴𝐿𝐿 →  𝐴𝐴𝑀𝑀𝐿𝐿 + 𝐿𝐿𝐿𝐿𝑖𝑖) hydrolyses is needed. This is equivalent to 𝑛𝑛𝐴𝐴𝐴𝐴𝐿𝐿
→  𝑛𝑛𝐴𝐴𝑀𝑀𝐿𝐿 + 2𝑛𝑛𝐿𝐿𝑖𝑖. 
Furthermore, 1 𝐺𝐺𝐴𝐴𝐿𝐿 →  𝐺𝐺𝑀𝑀𝐿𝐿 + 2𝐿𝐿𝑖𝑖 is required for initiation along with the energy from 
(2𝑛𝑛 − 2) 𝑚𝑚 (𝐺𝐺𝐴𝐴𝐿𝐿 → 𝐺𝐺𝑀𝑀𝐿𝐿 + 𝐿𝐿𝐿𝐿𝑖𝑖) for the peptide bonds. This is equivalent to:  
(𝑛𝑛 − 1)𝐺𝐺𝐴𝐴𝐿𝐿 → (𝑛𝑛 − 1)𝐺𝐺𝑀𝑀𝐿𝐿 + 2(𝑛𝑛 − 1)𝐿𝐿𝑖𝑖. In total, 𝑛𝑛𝐺𝐺𝐴𝐴𝐿𝐿 → 𝑛𝑛𝐺𝐺𝑀𝑀𝐿𝐿 + 2𝑛𝑛𝐿𝐿𝑖𝑖 are 
required to combine 𝑛𝑛 AAs. 
To sum up, 𝑛𝑛𝐴𝐴𝐴𝐴𝐿𝐿 →  𝑛𝑛𝐴𝐴𝑀𝑀𝐿𝐿 + 2𝑛𝑛𝐿𝐿𝑖𝑖 and 𝑛𝑛𝐺𝐺𝐴𝐴𝐿𝐿 →  𝑛𝑛𝐺𝐺𝑀𝑀𝐿𝐿 + 2𝑛𝑛𝐿𝐿𝑖𝑖 are needed to 
combine 𝑛𝑛 AAs. Thus, for 𝑛𝑛 AAs, the general equation is: 
𝒏𝒏𝑨𝑨𝑨𝑨𝒔𝒔 + 𝒏𝒏𝑨𝑨𝒅𝒅𝑷𝑷 + 𝒏𝒏𝒏𝒏𝒅𝒅𝑷𝑷→  𝒏𝒏𝑨𝑨𝒏𝒏𝑷𝑷 + 𝒏𝒏𝒏𝒏𝒏𝒏𝑷𝑷 + 𝟒𝟒𝒏𝒏𝑷𝑷𝒊𝒊 + 𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝒂𝒂𝑪𝑪𝑪𝑪𝒏𝒏.  
where 𝑛𝑛 represents the sum of the stoichiometric coefficients for every AA in the 
reaction. For the collagen synthesis reaction 𝑛𝑛 =  1446 
2.2.8.3 Acto-Myosin Complex in skeletal muscle 
Actin and myosin are the major contractile proteins in the skeletal muscle and for a 
muscle to grow, these protein filaments must both increase in number and proportion 
and be assembled in a manner which retains the structural make-up of the sarcomere. 
The number of myofibrils in a muscle increases, which in turn leads to an increase in the 
number of these contractile proteins. In humans, contractile protein synthesis is the key 
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process involved in the muscle mass regulation. Thus, it is important that any model 
constructed should focus on the synthetic arm of this process. 
In order to do this, a system of reactions that simulated the contractile protein synthesis 
during muscle growth was constructed. Firstly, the AA sequences for actin (alpha 
skeletal muscle) and myosin (type I) were downloaded from UniProt (www.uniprot.org). 
Then, similarly to that undertaken and described with collagen in section 2.2.7.2, letters 
in the AA sequence were counted using Python and the occurrence of every letter was 
incorporated as a stoichiometric coefficient for the corresponding AA. Energy demands 
were also considered in the reaction (as described in section 2.2.7.2). The general form 
of the reactions for both actin and myosin are: 
𝒏𝒏𝑨𝑨𝑨𝑨𝒔𝒔 + 𝒏𝒏𝑨𝑨𝒅𝒅𝑷𝑷 + 𝒏𝒏𝒏𝒏𝒅𝒅𝑷𝑷→ 𝒏𝒏𝑨𝑨𝒏𝒏𝑷𝑷 + 𝒏𝒏𝒏𝒏𝒏𝒏𝑷𝑷 + 𝟒𝟒𝒏𝒏𝑷𝑷𝒊𝒊 + 𝑨𝑨𝑨𝑨𝒅𝒅𝒊𝒊𝒏𝒏 and 
𝒏𝒏𝑨𝑨𝑨𝑨𝒔𝒔 + 𝒏𝒏𝑨𝑨𝒅𝒅𝑷𝑷 + 𝒏𝒏𝒏𝒏𝒅𝒅𝑷𝑷→ 𝒏𝒏𝑨𝑨𝒏𝒏𝑷𝑷 + 𝒏𝒏𝒏𝒏𝒏𝒏𝑷𝑷 + 𝟒𝟒𝒏𝒏𝑷𝑷𝒊𝒊 + 𝒏𝒏𝑴𝑴𝑪𝑪𝒔𝒔𝒊𝒊𝒏𝒏   
where 𝑛𝑛 represents the sum of the stoichiometric coefficients for every AA in the 
reaction. For actin building reaction 𝑛𝑛 = 377, while for myosin building reaction 𝑛𝑛 =
 1939. 
Then, the stoichiometric (molar) ratio for actin and myosin was considered to be 6:1 in 
the contractile complex (Murakami et al. 1985). Finally, a demand reaction for the 
production of Acto-Myosin complex was considered. This reaction served as the main 






Chapter 3: Reconstruction and analysis of fibroblast and TGF-β-
stimulated fibroblast cells using constraint-based methods 
3.1 Introduction 
Wound healing is a complex and dynamic process that involves multiple cell types. 
Fibroblasts play a key role in the process of wound healing. When injury occurs, these 
cells migrate to the site of the injury and differentiate into myofibroblasts which 
contract the wound by virtue of their contractile properties. Myofibroblasts express α-
SMA, which is considered the primary marker for the myofibroblast phenotype and TGF-
β has been shown to regulate the expression of this actin (Desmoulière et al. 1993). 
Following wound repair, myofibroblasts undergo apoptosis. However, pathological 
cases are characterised by myofibroblasts’ sustained presence, abnormal proliferation 
of these cells and excessive collagen production. In fibrotic diseases, TGF-β is reported 
to stimulate these biological functions. (Verrecchia et al. 2007).  
A metabolic model of the myofibroblast cell would be important for identifying 
metabolic pathways of chemical reactions in myofibroblast cells that might serve as 
therapeutic strategies to inhibit both proliferation and collagen deposition. Here two 
genome-scale metabolic models for FBN and FBTGF are presented. FBTGF is a commonly 
used in vitro model of the myofibroblast cell (Desmoulière et al. 1993). The two models 
were analysed separately and then compared using constraint-based tools such as FBA, 
FVA and GEA. Many of the predictions generated by computational simulations were 
independently validated in vivo. These models could illustrate a fundamental 
computational counterpart for interpreting transcriptomics data characterizing 
myofibroblast metabolic alterations in IPF. Identifying and understanding IPF hallmarks 
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is crucial for designing new therapeutic targets that will limit myofibroblast proliferation 
and collagen production.  
3.2 Methods 
3.2.1 Manual refinement 
A manual refinement of the models was performed as described in section 2.2.5. Due to 
the “restrictive” nature of FASTCORE algorithm, certain reactions can be excluded from 
the model. In this scenario, missing reactions that were not picked up by FASTCORE can 
be “forced” into the model. Firstly, the models were constructed without any essential 
reactions set. Then, after inspection, reactions such as essential exchanges were added 
in the essential reactions set and forced to carry flux. Furthermore, new reactions such 
as collagen synthesis or biomass reactions were also included in the set. In this 
framework, the essential reaction set was comprised of biomass reaction, collagen 
synthesis reaction and the exchange reactions for collagen, lactate and water.  
Subsequently, constraints (upper and lower bounds) were imposed for glucose, oxygen, 
and AA uptake and lactate secretion exchange reactions to improve model 
contextualisation. The majority of non-essential AAs were considered to have no influx 
(a lower bound of zero) as the model should be able to produce them (internally). An 
exception was made for glutamine, serine, asparagine and aspartic acid which were 
reported to be consumed by the cells (Dietmair et al. 2012). Hence these amino acids 
were made available in the model by imposing a non-zero lower bound. All the 
constraints for the uptake/secretion rates were derived from literature: oxygen 
(Bernard et al. 2015), AAs, glucose, lactate (Dietmair et al. 2012). For some rates, data 
from human embryonic kidney 293 (HEK 293) cells were used (Dietmair et al. 2012). 
These cells, which although of uncertain origin with respect to parent cell type, have 
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some morphological features of fibroblasts and may be of that origin (Stepanenko et al. 
2015). All rates were converted to mmol gDW-1 h-1, which was the chosen unit for fluxes. 
Where necessary, transformations were performed to obtain this unit. In order to 
perform some of these transformations, the dry weight of a single myofibroblast (843 
picograms) was derived from literature (Lee et al. 1977). As substrate uptake rates for 
FBN and FBTGF are significantly different, where possible, individual constraints for FBTGF 
fibroblast cells were used. In the absence of data, the uptake/secretion bounds in the 
FBTGF model were estimated using the bounds in the FBN model. TGF-β was reported to 
increase AA uptake in lung fibroblasts by approximately two fold (Subramanian et al. 
2006). Thus, lower bounds for AA exchanges in the FBTGF model were calculated by 
doubling the constraints for FBN. Furthermore, in vivo studies also reported a 2.5 
increase in lactate production (Zhang et al. 2015) and an increase by approximately two 
fold in glucose uptake for FBTGF when compared to FBN. Thus, the lower bound for 
glucose uptake and the upper bound for lactate efflux in the FBTGF model were derived 
in the same way as AAs (by doubling the bounds from the FBN model). The constraints 
for the remaining reactions in the model were not amended. Tables 6.2.1-6.2.2 in the 
Appendices section contain a complete list for the imposed constraints in the FBN and 
FBTGF models. Lastly, FASTCC was run again to identify flux inconsistent reactions. These 
reactions were then removed from the model. A threshold of 1 x 10-6 was chosen for the 
FASTCC workflow. 
3.2.2 Model analysis 
A biomass objective function was used to simulate myofibroblast proliferation. FBA was 
employed to assess the metabolic fluxes of glycolysis during proliferation in the FBN and 
FBTGF models. Firstly, the bioavailability of glucose was increased by leaving 
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corresponding exchange reaction unconstrained (lower bound equals -1000). Then, FBA 
computed the maximal biomass rate. Flux rates for the glycolytic reactions in the FBTGF 
model were then compared with those in the FBN model. Next, FBA computed the 
maximal optimal flux for the collagen synthesis reaction in both models. FVA was used 
to assess alternate optimal solutions for a computed FBA with collagen synthesis as the 
objective function. FVA provides a range of fluxes (maximum and minimum flux) that a 
reaction can carry to achieve the same optimal value for the objective function. Then, 
flux span ratios were used to assess the essentiality of each reaction to the collagen 
production reaction. These flux spans and ratios were sorted in ascending order and 
those reactions with the smallest flux span or ratio were considered essential for the 
collagen synthesis. Single gene deletion was used to assess the essentiality of all genes 
in the model to collagen synthesis. This method provided a list of genes that impacted 
collagen synthesis and the calculated collagen synthesis rate for each gene that is 
deleted. To get the most essential genes out of that list, one can set a tolerance level 
(threshold) for the collagen synthesis rate. Next, genes whose deletion would generate 
a synthesis rate lower than threshold can be identified. The lower the threshold, the 
greater the essentiality of that gene to the objective reaction. Escher (King et al. 2015) 
was used to visualise the metabolic pathways and flux distributions from the model. 
3.3 Results 
3.3.1 Model generation 
RNA-seq data were used to generate two separate models for the FBTGF and FBN. These 
genome-scale models were constructed and refined using identical methods (as 
described in a previous section). The final version of the FBN model accounts for 1673 
genes, 2949 reactions and 2012 metabolites while the final FBTGF model accounts for 
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1673 genes, 2909 reactions and 1994 metabolites. These models were made publicly 
available (GitHub Repository https://github.com/andreidob91/cobramodels). The reactions 
in the FBN model are distributed over 81 metabolic processes (subsystems) while the 
reactions in the FBN model account for 80 metabolic processes (Fig. 3.3 - 3.4). 
Interestingly, the only metabolic process that appears in the FBN model and is not part 
of the FBTGF model is histidine metabolism. In the FBN model, histidine metabolism is 
represented by three reactions which involve histamine (catabolism of histamine). 
Differential data have been reported on the effects of histamine on fibroblast biology 
such as differentiation (Gailit et al. 2001, Lin et al. 2015) and although most reports 
suggest pro-fibrotic mechanisms (Kohyama et al. 2009), the effects of histamine may be 
context specific (Jordana et al. 1988). In support of a pro-fibrotic role for histamine, the 
presence of mast cells (which are the major source of histamine) has been noted in 
fibrotic lesions (Levick et al. 2018). However, in this case, the gene expression data and 
modelling work may suggest a negative effect of histamine on fibroblast differentiation. 
The metabolites in both models are distributed over 9 compartments (cytosol, 
extracellular, Golgi apparatus, mitochondrial intermembrane space, lysosome, 
mitochondria, nucleus, endoplasmic reticulum and peroxisome). Figures 3.1 - 3.4 detail 
the reaction distribution and metabolite compartmentalisation in both the FBN and FBTGF 
model. Cytosol contains the greatest number of metabolites in the FBTGF and FBN models, 
followed by mitochondria. In terms of reaction distribution over metabolic processes, 









Figure 3.1 Compartmentalisation of metabolites in the FBN model 
This bar chart shows the cellular compartments in the FBN model sorted by the number of 




Figure 3.2 Compartmentalisation of metabolites in the FBTGF model 
This bar chart shows the cellular compartments in the FBTGF model sorted by the number of 





































































Figure 3.3 Reaction distribution over metabolic processes in the FBN model  
This bar chart shows the metabolic processes in the FBN model sorted by the number of 




Figure 3.4 Reaction distribution over metabolic processes in the FBTGF model  
This bar chart shows the metabolic processes in the FBTGF model sorted by the number of 




3.3.2 Flux balance analysis 
FBA showed that the biomass flux rate was higher in the FBTGF model, compared to the 
FBN model (Table 3.1). Histidine was the first limiting AA in both models when they were 
optimised towards biomass production (Table 3.2-Table 3.3). Histidine is not synthesised 
internally by the model and is imported directly in the biomass reaction. Thus, the 
difference between the maximal biomass fluxes is mainly attributed to histidine uptake 
rate which is two times higher in the FBTGF model compared to the FBN model. If the 
lower bound for histidine uptake is doubled in the FBN, the next limiting factor for 
biomass reaction is oxygen (followed by glucose, lysine etc.). When the same exchange 
constraints were imposed in the FBTGF and FBN models, the corresponding maximal 
fluxes for biomass production were equal and the models utilised very similar pathways 
to produce biomass. 
The biomass objective function was further used to investigate metabolic 
reprogramming of FBN and FBTGF during proliferation, focusing on glycolysis. When 
optimising towards the biomass objective function (proliferation), there was a 2-fold 
increase in glucose uptake in the FBTGF model compared to FBN model. Furthermore, all 
rate-limiting glycolytic reactions such as HK, PFKM and PKM were predicted to have 
higher metabolic fluxes in the FBTGF model cells compared to FBN due to a higher glucose 
uptake rate. In consequence, the lactate production flux was higher in the FBTGF model 
by 2-fold. In vivo studies have reported a 2.5-fold increase in lactate production for FBTGF 
(Zhang et al. 2015). These results are in full agreement with the Warburg effect and the 
previously mentioned studies (Xie et al. 2015, Zank et al. 2018) which have reported that 
TGF-β stimulates glycolysis during myofibroblast proliferation in fibrotic diseases. Table 
3.2 details these fluxes in both FBTGF and FBN models. It is important to point out that 
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these flux differences in the FBTGF and FBN reactions are determined by the differences 
in the exchange constraints. 
Table 3.1 Maximal fluxes for biomass reaction in the FBN and FBTGF models 
Biomass Production Rate (mmol gDW-1 h-1) 
FBN FBTGF 
0.013 0.027 
*Flux rates were determined using Flux Balance Analysis 
 
Table 3.2 The lower bounds in the FBN model vs. the actual uptake/secretion rates when 
optimising for biomass production 





uptake rate  
mmol h-1 
gDW-1) 
Ub (max secretion rate 
mmol h-1 gDW-1) 
Uptake rate 
(mmol gDW-1 h-1) 
Secretion rate 
(mmol gDW-1 h-1) 
Glc -0.5280 0 -0.0863 N/A 
Gln -0.0290 1000 -0.0115 N/A 
Arg -0.0160 1000 -0.0086 N/A 
Asn -0.0041 1000 -0.0026 N/A 
Asp -0.0063 1000 -0.0054 N/A 
His -0.0032 1000 -0.0032 N/A 
Leu -0.0190 1000 -0.0087 N/A 
Lys -0.0120 1000 - 0.0074 N/A 
Ile -0.0130 1000 -0.0022 N/A 
Met -0.0049 1000 - 0.0020 N/A 
Phe -0.0058 1000 -0.022 N/A 
Ser -0.0370 1000 -0.0046 N/A 
Thr -0.0084 1000  -0.0026 N/A 
Trp -0.0015 1000 -7.32x10-4 N/A 
Tyr -0.0046 1000 -0.0017 N/A 
Val -0.0140 1000 -0.0031 N/A 
Lac 0 0.695 N/A 0.0038 




Table 3.3 The lower bounds in the FBTGF model vs. the actual uptake/secretion rates when 
optimising for biomass production 
Exchange 
Reaction 
Lb (max uptake 
rate 
mmol gDW-1 h-1) 
Ub (max 
secretion rate 
mmol gDW-1 h-1) 
Uptake rate (mmol 
gDW-1 h-1) 
Secretion rate (mmol 
gDW-1 h-1) 
Glc -1.056 0 -0.2409 N/A 
Gln -0.058 1000 -0.0303 N/A 
Arg -0.032 1000 -0.0172 N/A 
Asn -0.0082 1000 -0.0052 N/A 
Asp -0.0126 1000 N/A  N/A 
His -0.0064 1000 -0.0064 N/A 
Leu -0.0380 1000 -0.0175 N/A 
Lys -0.0240 1000 -0.0148 N/A 
Ile -0.0260 1000 -0.0045 N/A 
Met -0.0098 1000 -0.0041 N/A 
Phe -0.0116 1000 -0.0043 N/A 
Ser -0.0740 1000 -0.0171 N/A 
Thr -0.0168 1000  -0.0053 N/A 
Trp -0.0030 1000 -0.0015 N/A 
Tyr -0.0920 1000 -0.0033 N/A 
Val -0.0280 1000 -0.0061 N/A 
Lac 0 1.39 N/A 0.1390 
O2 -0.3560 1000 -0.3560 N/A 










Table 3.4 Maximal flux rates for glycolytic reactions in the FBN and FBTGF models when optimising 
for biomass production 
*Flux rates were determined using Flux Balance Analysis  
 
FBA results also showed a higher collagen production rate in the FBTGF model compared 
to the FBN model (Table 3.5). FBTGF also display a higher collagen production in vivo 
compared to FBN. The maximum collagen synthesis rate in the FBTGF model was 0.000374 
mmol gDW-1 h-1, similarly to the in vitro rate of 0.000712 mmol gDW-1 h-1 (Illsley et al. 
2000).  
Oxygen, glutamine, aspartate, asparagine, isoleucine, threonine, valine and serine were 
hitting their uptake limits in the FBN model when it was optimised for collagen 
production (Table 3.6). The lower bounds for these uptake rates were higher in the FBTGF 
Reaction Flux rate (mmol gDW-1 h-1) 
FBN FBTGF 
Glucose Uptake 0.08 0.17 
HK 0.08 0.17 
GPI 0.03 0.07 
PFKM 0.03 0.001 
ALDOA 0.03 0.08 
TPI 0.03 0.07 
GAPDH 0.07 0.15 
PGK 0.07 0.15 
PGAM 0.07 0.15 
ENO 0.07 0.15 
PKM 0.07 0.15 
Lactate Efflux 0.07 0.13 
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model hence the increase in the collagen synthesis flux. Glycine was also required for 
collagen synthesis and no external uptake was considered for it. Thus, the maximisation 
of the collagen synthesis function is also dependent on the import/synthesis of serine 
which was converted to glycine through SHMT. When optimising for collagen synthesis, 
FBA also showed that the flux rates for PHGDH, PSPH, PSAT and SHMT1 were higher in 
the FBTGF model compared to FBN model (Table 3.8). Serine is imported in the model and 
then combines with the serine generated from the glycolysis-diverted PSPH reaction to 
produce glycine through SHMT reaction (Fig. 3.5 a-b). Owing to higher uptakes for serine 
and glucose, the fluxes corresponding to the de novo serine-glycine pathway are higher 
as well. 
Table 3.5 Maximal flux rates for collagen synthesis rate in FBN and FBTGF models 
Collagen Synthesis Rate (10-4 mmol gDW-1 h-1) 
FBN FBN 
1.86 3.74 
*Flux rates were derived using Flux Balance Analysis 
 
With a higher glucose and oxygen availability, glycolysis and the TCA cycle also display 
higher fluxes in the FBTGF model. Although in very small numbers, the fluxes 
corresponding to the Pentose Phosphate Pathway (PPP) are lower in the FBTGF model 
compared to FBN model. One significant difference between the models is related to the 
metabolic fate of pyruvate. With a higher glucose uptake, the cytosolic pyruvate 
accumulates and is converted to cytosolic lactate through LDHA. Forty six percent of 
lactate is secreted out of the model through the lactate exchange reaction. However, 
the amount of lactate exceeds the upper bound of the lactate exchange reaction (the 
exchange reaction is hitting its secretion limits) and the remaining 53% is transported to 
mitochondrial lactate and then converted to mitochondrial pyruvate through lactate 
dehydrogenase B (LDHB). Next, pyruvate dehydrogenase (PDH) converts mitochondrial 
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pyruvate to acetyl-CoA which replenishes the TCA cycle. In the FBN model, the cytosolic 
pyruvate is converted to cytosolic lactate through LDHA and most of the lactate (97%) is 
secreted out of the model through the lactate exchange reaction. The remaining 3% is 
transported to mitochondria and converted to pyruvate. Mitochondrial pyruvate is then 
converted to oxaloacetate through pyruvate carboxylase (PC) reaction. Figure 3.5 (a-b) 
details these processes in greater detail.  
Table 3.6 The lower bounds in the FBN model vs. the actual uptake/secretion rates when 
optimising for collagen synthesis 





reaction    
Lb (max uptake rate  
mmol h-1 gDW-1) 
Ub (max secretion rate 
mmol h-1 gDW-1) 
Uptake Rate Secretion 
Rate 
Glc -0.5280 0 -0.03811 N/A 
Gln -0.0290 1000 -0.0290 N/A 
Arg -0.0160 1000 -0.0133 N/A 
Asn -0.0041 1000 -0.0041 N/A 
Asp -0.0063 1000 -0.0063 N/A 
His -0.0032 1000 -0.0017 N/A 
Leu -0.0190 1000 -0.0090 N/A 
Lys -0.0120 1000 -0.0106 N/A 
Ile -0.0130 1000 -0.0130 N/A 
Met -0.0049 1000 -0.0024 N/A 
Phe -0.0058 1000 -0.050 N/A 
Ser -0.0370 1000 -0.0370 N/A 
Thr -0.0084 1000  -0.0084 N/A 
Trp -0.0015 1000 -0.0011 N/A 
Tyr -0.0046 1000 -0.0024 N/A 
Val -0.0140 1000 -0.0140 N/A 
Lac 0 0.695 N/A 0.695 
O2 -0.178 1000 -0.35 N/A 
86 
 
Table 3.7 The lower bounds in the FBTGF model vs. the actual uptake/secretion rates when 
optimising for collagen synthesis 
*Flux rates were determined using Flux Balance Analysis 
 
Table 3.8 Maximal flux rates for the reactions serine/glycine biosynthetic pathway when 
optimising for collagen production  
Reaction Flux rate (mmol gDW-1 h-1) 
FBN FBTGF 
PHGDH 0.021 0.094 
PSAT 0.021 0.094 








Lb (max uptake rate  
mmol h-1 gDW-1) 
Ub (max secretion rate 
mmol h-1 gDW-1) 
Uptake Rate Secretion 
Rate 
Glc -1.056 0 0.44 N/A 
Gln -0.058 1000 -0.058 N/A 
Arg -0.032 1000 0.026 N/A 
Asn -0.0082 1000 -0.0082 N/A 
Asp -0.0126 1000 -0.0126 N/A 
His -0.0064 1000 -0.0034 N/A 
Leu -0.0380 1000 -0.0303 N/A 
Lys -0.0240 1000 -0.0213 N/A 
Ile -0.0260 1000 -0.0090 N/A 
Met -0.0098 1000 -0.0049 N/A 
Phe -0.0116 1000 -0.0101 N/A 
Ser -0.0740 1000 -0.0740 N/A 
Thr -0.0168 1000 -0.0168 N/A 
Trp -0.0030 1000 -0.0022 N/A 
Tyr -0.0920 1000 -0.0920 N/A 
Val -0.0280 1000 -0.0280 N/A 
Lac 0 1.39 N/A 1.39 














Figure 3.5 The metabolic maps describing the glycolysis, pentose phosphate pathway and TCA 
cycle in the FBN (a) and FBTGF (b) models when collagen synthesis is optimised  
Following its uptake, glucose is transported to cytosol where converted to pyruvate. Pyruvate 
replenishes the TCA cycle through different reactions: In the FBN model, pyruvate is converted to 
oxaloacetate through PC reaction to form oxaloacetate, while in the FBTGF model, pyruvate is 
oxidised via PDH reaction to form acetyl-CoA. The rest of pyruvate is converted to lactate and 
exported to the extracellular compartment through lactate exchange reaction. Due to higher 
uptake rates for glucose and oxygen, glycolysis and TCA cycle display higher fluxes in the FBTGF 
model. Although with very small fluxes, PPP is present in both model and displays lower fluxes in 
the FBTGF model. The de novo serine-glycine is present in both models and uses the 3-PG flux to 
produce serine which is further converted to glycine. Line thickness and colour (thin grey to bold 
red) are indicators of the flux values (low to high). The reactions which have no data in the model 
are coloured in orange. Escher (King et al. 2015) was used to generate the metabolic maps and 





3.3.3 Flux variability analysis and flux spans 
FVA and flux spans were used to rank reactions based on their essentiality to collagen 
synthesis. Four reactions from BCAA metabolism which generate precursors (NADH and 
FADH2) for oxidative phosphorylation appear in the top of the list. After this, electron 
transport chain reactions follow. Collagen production requires energy and oxidative 
phosphorylation is the primary source of ATP in the cell. Subsequently, the rest of the 
ATP needed for collagen synthesis is produced through glycolysis. Thus, TCA cycle and 
glycolytic reactions are also expected to be identified as essential. Table 3.9 details the 
results generated by flux spans. 
Table 3.9 Reactions with smallest relative flux span when optimising FBTGF model for collagen 
synthesis   
Rank Reaction Flux span value Metabolic Pathway 
1 ACAD9 1.00 Valine, Leucine, and 
Isoleucine Metabolism 
2 HIBADH 1.00 Valine, Leucine, and 
Isoleucine Metabolism 
3 BCKDHA 1.00 Valine, Leucine, and 
Isoleucine Metabolism 
4 ACAD8 1.62 Valine, Leucine, and 
Isoleucine Metabolism 
5 COX 34.73 
 
Oxidative Phosphorylation 
6 NDUFA10 34.73 
 
Oxidative Phosphorylation 
7 ATP5F1B 34.73 
  
Oxidative Phosphorylation 
8 HK 735.37 
 
Glycolysis 
9 FH 999.07 
 
Citric Acid Cycle 
10 PKM 1246.21 Glycolysis 
 
3.3.4 Gene essentiality analysis 
Single in silico gene deletion identified a total of 581 genes that impacted (reduced) 
collagen synthesis rate. Most of them only had a minor effect on the collagen production 
reaction when deleted (Fig. 3.7). An initial threshold of zero was set for the synthesis 
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rate of collagen. Deletion of PYCR1 and SHTM1 results in a collagen synthesis rate of 
zero. Based on the current analysis, these genes are essential for collagen synthesis. The 
first one is an encoding of the enzyme that catalyses the last step of proline biosynthesis. 
The proline uptake rate was not set in the model and a good proportion of a collagen 
molecule is comprised of proline (23%). Furthermore, proline is used in used in many AA 
transport reactions hence this gene becomes essential for collagen synthesis. This fact 
is in agreement with the result generated by FVA which was discussed in the previous 
section. The second gene, SHTM1, encodes the cytosolic enzyme that catalyses the final 
step of glycine synthesis from serine. With no import of glycine in the model, the glycine 
synthesis is dependent on the SHMT gene which converts serine to glycine. Next, the 
threshold was progressively increased until it reached about half of the initial collagen 
synthesis rate. In this case, four more genes were identified: CS, PHGDH, PSPH, PSP 
(Table 3.10). This implies that deletion of these genes reduces the maximal collagen 
production rate by about 50%. CS encodes the rate-limiting enzyme catalysing the 
synthesis of citrate from oxaloacetate and acetyl-CoA in the first step of TCA cycle. The 
other three genes, PHGDH, PSPH and PSAT encode the enzymes catalysing the first three 
steps in the de novo serine-glycine pathway. 
When CS was deleted and the model optimised for collagen production, the TCA cycle 
was reduced, but not entirely supressed. CS catalyses the initial reaction of the TCA cycle 
in which citrate is produced from acetyl-CoA and oxaloacetate. With the citrate synthase 
(CS) reaction being switched off, the next two reactions in the cycle, aconitate hydratase 
(ACO2) and isocitrate dehydrogenase (IDH2) were also supressed. 2-oxoglutarate 
dehydrogenase (OGDH) carried on with a very small flux as α-ketoglutarate was 
produced through alternative pathways in very small quantities. In this scenario, the 
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entire amount of succinyl-CoA was produced through an alternative but less efficient 
pathway involving the metabolism of valine. Hence the amount of ATP produced 
anaerobically was reduced. Under normal circumstances, 10.5% of the PGK flux is 
diverted into the de novo serine-glycine pathway via 3-PG and used to synthesise serine 
which is further converted to glycine. When CS is switched off, the entire flux for PGK is 
used to produce ATP and nothing is diverted into the de novo serine-glycine pathway. 
Furthermore, glycolysis continues as 3-PG is produced through an alternative pathway 
which includes the use of fructose and mannose metabolism. Thus, with no serine 
produced internally, the production of glycine relies entirely on the amount of serine 
which is imported through the exchange reaction hence the reduction in collagen 












Figure 3.6 The metabolic maps describing the glycolysis, de novo serine-glycine pathway and TCA 
cycle in the FBTGF model with CS reaction being on (a) and off (b) when optimising for collagen 
synthesis  
Following the deletion of CS gene, ACO2 and IDH3 reactions are stopped. In this framework, the 
flux corresponding to reaction is used to produce ATP and the serine/glycine synthesis relies only 
on the import of serine from the extracellular compartment. In consequence, the synthesis of 
collagen is reduced. At the same time, glycolysis carries on as 3-PG is produced through an 
alternative pathway. Line thickness and colour (thin grey to bold red) are indicators of the flux 
values (low to high). The reactions which have no data in the model are coloured in orange. 
Escher (King et al. 2015) was used to generate the metabolic maps and visualise the flux 




A question that could arise is why mitochondrial CS was the only TCA cycle enzyme that 
became critical to collagen synthesis? One answer could be that Recon 2.2 does not 
provide a complementary gene for the mitochondrial CS or alternative routes to produce 
the necessary amount of α-ketoglutarate to maintain the initial flux of the collagen 
synthesis. When the other TCA cycle genes were subjected to single gene deletion, the 
model was able to find alternative genes/enzymes to maintain the TCA cycle running 
and produce enough α-ketoglutarate which guaranteed the optimal production of 
glycine through the de novo serine-glycine pathway. For instance, when the cytosolic 
aconitase (ACO1) was supressed, mitochondrial aconitase (ACO2) was used by the 
model to maintain the initial flux and vice-versa. It is important to point out that a 
combinatorial deletion of these genes (ACO1 and ACO2) would be critical to collagen 
synthesis reducing it to zero flux rate. Similarly, when the NADP+-dependent isocitrate 
dehydrogenase (IDH2) was supressed, the NAD+-dependent isocitrate dehydrogenase 
(IDH3) was used to produce α-ketoglutarate and the initial flux was maintained. When 
OGDH was deleted, dihydrolipoyllysine-residue succinyltransferase (DLST) was used to 
produce the necessary amount of succinyl-CoA and maintain the initial flux. When 
succinyl-CoA ligase (SUCLG1) was deleted, succinic semialdehyde dehydrogenase 
ALD5A1 was used to produce succinate. The deletion of succinate dehydrogenase 
(SDHA) and fumarate hydratase (FH) enabled the use of internal metabolic routes to 
produce fumarate and malate and maintain the initial collagen synthesis flux. Finally, 
when the mitochondrial malate dehydrogenase (MDH2) was deleted, the cytoplasmic 
malate dehydrogenase (MDH1) was used to maintain the initial flux.   
Single gene deletion in the FBTGF model also identified PHGDH, PSPH, PSAT as critical 
genes for collagen production. Furthermore, SHMT was identified to be essential for 
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collagen production. These genes are encoding those enzymes that catalyse reactions 
involved in glycine and serine de novo synthesis. The analysis for the FBTGF model 
provided evidence for de novo serine-glycine biosynthetic pathway, identifying the 
correct reactions, enzymes and genes involved in this process and their essentiality for 
collagen production. This is an important result as TGF-β appears to play a vital role in 
regulating the gene expression of the enzymes involved in the serine de novo synthesis. 
The importance of this pathway to collagen synthesis will be further discussed in section 
3.4. 
Table 3.10 Single gene deletion results in the FBTGF model 
Deleted Gene Collagen Synthesis Rate (mmol gDW-1 h-1 x 10-4) % reduction in the max 
collagen synthesis rate 
 
SHMT1 0 100%  
PYCR1 0 100%  
CS 1.44 61%  
PSPH 1.64 56%  
PHGDH 1.64 56%  
PSAT1 1.64 56%  
*Deletion of SHMT1 and PYCR1 resulted in a collagen synthesis rate of zero. Deletion of CS reduce 
the collagen synthesis rate by 61%, while deletion of PSPH, PHGDH and PSAT1 reduced the 







Figure 3.7 Gene essentiality analysis in the FBTGF model 
The collagen synthesis rate after single gene deletion (Y axis) is plotted against the deleted genes 
(X axis). Deletion of most genes had a minor effect on the collagen synthesis reactions. These 
genes are plotted very near to the collagen synthesis rate (3.74 x 10 -4 mmol gDW-1 h-1). Deletion 
of SHMT1 and PYCR1 genes generated a zero collagen synthesis rate and these genes were 
considered essential for the objective function. Deletion of PHGDH, PSAT1 and PSPH reduced the 
collagen synthesis rate to 1.64 x 10-4 mmol gDW-1 h-1 while deletion of CS gene reduce it to 1.44 
x 10-4 mmol gDW-1 h-1. These genes were considered critical to collagen synthesis. 
 
In order to make sure that the results described earlier were not influenced by the fact 
that for certain AAs the uptake rates were not provided, an analysis was performed with 
these AAs being exchanged (influx was allowed). As was mentioned in the methods 
section, the alanine, proline, glycine, cysteine AAs were reported not to be consumed 
by the cells and have their corresponding lower bound equal to zero. For cysteine and 
glutamate, the exchange reactions were not picked up in the initial model building 
process by FASTCORMICS. As outlined in section 3.2.1, if these exchanges were not a 
part of the core set, they were likely to be removed and the model was able to produce 
them internally. To perform this analysis, the corresponding exchange reactions for 
glutamate and cysteine were manually added to the model. 
 Given that there were no uptake rates for any of these AAs in the literature data source, 








































for all consumed AAs. In this framework, the model was optimised for collagen 
production. No significant changes were observed. However, there was a slight decrease 
in the percentage by which collagen synthesis dropped when PHGDH, PSPH, PSAT were 
deleted (from 56.1% to 39.5%). With glycine and proline uptake in place, the essentiality 
of the serine-glycine metabolic pathway was reconfirmed, and the same genes were 
predicted as critical/essential by the GEA with the exception of PYCR1, which was 
responsible to produce proline in the absence of an uptake rate for this AA. It is 
important to point out that the uptake of glycine was not able to fully compensate for 
the amount of glycine needed by collagen synthesis and the serine-glycine pathway 
remains essential to the production of collagen. 
3.3.5 Differential expression analysis 
Differential expression analysis was used to investigate the change in the expression 
levels under “control” and “TGF-β-stimulated” conditions. In this way, the results 
generated from FBA, FBA-based GEA and FVA could be verified using a method which is 
entirely based on “omics” data. Initially, the analysis produced a table containing 22110 
genes with non-zero total read count. Out of these, 4930 were up-regulated (p-adjusted 
value < 0.05) and 4813 were down-regulated (p-adjusted value < 0.05). The analysis also 
identified 1 outlier and 4139 genes with a low count number.  
Table 3.11 DEA results  




Outliers Low count 
22120                               4930  







*DEA results showing the total number of: genes analysed, up-regulated genes, down-regulated 
genes, outliers and genes with low count. 
 Next, a volcano plot was used to display the gene fold-change versus the statistical 
significance. Thus, genes involved in the glycine/serine pathway and the rate-limiting 
glycolytic genes were investigated using the volcano plot. The results showed that genes 
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coding for the enzymes involved in the glycine/serine pathway are up-regulated under 
TGF-β stimulation with the exception of SHMT1 whose fold-change was not statistically 
significant. However, SHMT2 was picked up as significantly up-regulated under TGF-β 
stimulation with a log2 fold-change of 2.01 and a p-value of zero. Thus, these results are 
consistent with FBA and GEA which showed that these genes are essential/critical for 
collagen production and the corresponding reactions have higher fluxes in the FBTGF 
model. Next, the genes coding for the rate-limiting glycolytic enzymes were also 
displayed in the volcano. The results showed no significant difference in gene expression 
for HK1, PKM, PFKM under TGF- β stimulation. HK1 were placed in the non-significant 
area of the plot while PFKM had a small p-value but a relatively small fold-change. These 
results are not consistent with the FBA results which showed higher fluxes for HK1, PKM 
and PFKM in the FBTGF model and with the in vivo studies which reported an upregulation 





Figure 3.8 Volcano plot displaying significance vs fold-change under TGF- β stimulation 
The X-axis represents the log2 fold-change while the Y-axis shows the negative log10 of the p-
value. The two vertical lines correspond to the up-regulated and down-regulated fold-change 
thresholds (-5,5) while the horizontal line represents the p-value threshold (0.05). Each dot in the 
figure represents a single gene. Red colour represents either an up-regulation (right) or a down-
regulation of the gene expression under TGF- β stimulation (high fold change and low p-value). 
Blue corresponds to low p-value but small fold-change, while green corresponds to high p-value 




Myofibroblast cells play a crucial role in supporting the wound healing process. They 
contract the wound and facilitate re-epithelisation. Under normal circumstances, 
myofibroblasts disappear through apoptosis. However, pathological cases such as 
fibrotic diseases are characterised by myofibroblast persistence, altered ECM and 
excessive collagen deposition. IPF is an idiopathic fibrotic disease that causes scarring in 
the lungs over time. The prognosis for IPF patients is poor and the available treatment 
can only relieve some symptoms. Some studies have reported that myofibroblasts 
metabolic reprogramming occurs in IPF (Xie et al. 2015, Zank et al. 2018). Although 
metabolic reprogramming has been thoroughly studied in cancer cells and glycolysis is 
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considered a drug target, this phenomenon has not been fully understood in fibrosis. 
TGF-β-induced myofibroblast differentiation has been associated with augmented 
glycolysis within the cell. Furthermore, in IPF patients, the de novo serine-glycine 
biosynthetic pathway and the enzymes catalysing the reactions in this pathway are 
reported to be up-regulated in IPF. Collagen has a unique AA build-up with about one 
third of collagen being glycine. Serine is diverted from glycolysis via 3-PG and then 
converted to glycine in a three-step enzymatic reaction. Thus, the de novo serine-glycine 
pathway constitutes a major metabolic pathway that is required for collagen synthesis. 
In IPF, TGF-β was reported to not only stimulate glycolysis, but also to upregulate the 
enzymes catalysing the reactions in the serine-glycine pathway (Nigdelioglu et al. 2016). 
Using the global human metabolic reconstruction, FASTCORMICS algorithm and 
transcriptomics data, two genome-scale metabolic models for the FBN and FBTGF cells 
were constructed. Initially, transcriptomics data generated from microarrays were used 
to generate a model for the myofibroblast cell. This was laser capture microdissection 
of human idiopathic pulmonary fibrosis lung samples collecting fibroblastic foci. The 
advantage of using microarray data was that of having a myofibroblast-specific gene 
signature in IPF. However, the limitation was that only a small amount of RNA was 
obtained, which resulted in an incomplete representation of gene expression in the 
cells. Given this limitation, transcriptomics data generated by RNA-seq from cultured 
fibroblasts was used as cultured fibroblasts provided sufficient RNA to perform deep 
RNA-seq. Human primary fibroblast cells from healthy volunteers were stimulated with 
TGF-β to induce myofibroblast phenotype. FBTGF is thought to more closely represent 
myofibroblast phenotype and IPF. These two data sets (FBN and FBTGF) gave us the 
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opportunity to produce two models and compare them using constraint-based 
methods. 
The model aimed to investigate whether metabolic reprogramming occurs in 
myofibroblasts using constraint-based methods such as FBA, FVA and GEA. Initially it 
was checked whether FBTGF model exhibits augmented glycolysis. The results showed 
that glucose uptake was higher in the FBTGF model when compared to the FBN model. 
Next, the rate-limiting reactions in glycolysis were found to display a higher maximal flux 
rate in the FBTGF model when compared to FBN model. Lactate secretion was also higher 
in the FBTGF model when compared to the FBN model. However, these differences in the 
fluxes were determined by the differences in the uptake rates for histidine and valine. 
The results from DEA did not confirm the hypothesis that the genes coding for rate-
limiting enzymes in glycolysis were up-regulated under TGF-β stimulation. However, this 
was confirmed by the aforementioned in vivo studies which may suggest that biological 
hypotheses cannot be gleaned from “omics” data alone. 
Next, the collagen production reaction was chosen as an objective function for the 
models and FBA was computed to calculate maximum collagen production rate. The 
model reported a higher collagen production rate in the FBTGF model compared to FBN 
model and displayed higher fluxes for the glycolysis and TCA cycle in the FBTGF model. In 
terms of the structure, the models use very similar pathways to produce collagen and 
the difference between the fluxes in the glycolysis and TCA cycle is attributed to the 
difference between uptake/secretion rates. However, one noticeable difference is the 
metabolic fate of pyruvate. In the FBN model, pyruvate is converted to oxaloacetate 
through PC, while in the FBTGF model pyruvate is converted to acetyl-CoA through PDH. 
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Having compared both models, the FBTGF model was analysed in more detail to identify 
potential drug targets. Following this, other FBA-based tools were employed to further 
assess the essentiality of certain reactions and genes to collagen production. FVA and 
GEA were used to identify which enzymes and genes are essential to collagen 
production. GEA identified PHGDH, PSPH and PSAT as critical genes to collagen 
production. SHMT was even found essential to collagen synthesis, its deletion 
generating zero collagen production rate. This result was encouraging as the model 
correctly predicted the fact that de novo serine-glycine pathway is important, even 
essential, to collagen production. It may be argued that this result could be influenced 
by the fact that glycine influx was not permitted in the model. To verify this hypothesis, 
the glycine import was temporarily allowed, and the same simulations were performed. 
GEA still identified SHMT as an essential gene while PHGDH, PSPH and PSPH were found 
critical to collagen production. 
Lastly, the fluxes of the key reactions involved in this pathway were evaluated. FBA was 
used to compare the fluxes in the FBN and FBTGF models. The results showed that flux 
rates for the reactions involved in serine/glycine biosynthesis were higher in the FBTGF 
model. The results were in agreement with an in vivo study published in 2016 
(Nigdelioglu et al. 2016). This paper describes several key roles of TGF-β in stimulating 
glycolysis, synthesis of glycine, serine and collagen in IPF patients. Firstly, the study 
reported that TGF-β upregulated glycolysis. However, transcriptional regulation of TGF-
β was not influenced by glycolysis. Thus, it was suggested that a glycolysis-diverted 
pathway may impact the TGF-β-stimulated collagen synthesis. Then, this paper aimed 
to investigate whether biosynthesis of serine/glycine was augmented in the presence of 
TGF-β. When the FBN and FBTGF cells were compared, it was reported that the gene 
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expression of the enzymes involved in serine/glycine biosynthesis (PHGDH, PSPH, PSAT, 
SHMT) was upregulated in the FBTGF. This is in full agreement with the results from FBA 
when the fluxes corresponding to these enzymes in both the FBTGF and FBN models were 
compared. Furthermore, this review also suggested that de novo synthesis of serine and 
its conversion to glycine were required for TGF-β-stimulated collagen production. In vivo 
gene knockout of PHGDH and SHMT2 led to lower collagen production when treated 
with serine and glycine in culture, compared to control. Moreover, TGF-β-stimulated 
collagen production was completely disabled when cells (with knockdowns of PHGDH 
and SHMT2) were not cultured with glycine or serine. In other words, PHGDH and 
SHMT2 were identified as essential genes. Thus, in silico single gene deletion generated 
similar results to in vivo gene knockout, with exception of PHGDH, which was not 
identified as essential gene to collagen synthesis. GEA only identified PHGDH as critical 
gene, whose deletion reduced the collagen synthesis by about 50%. In a separate 
analysis, DEA showed that under TGF-β stimulation, the gene expression levels for 
PHGDH, PSAT, PSPH, and SHMT were significantly up-regulated. This result is in 
agreement with the results generated from FBA which showed higher fluxes for the 
corresponding enzymes and can act as a confirmation for the essentiality of this 
metabolic pathway to collagen production in FBTGF.  
TGF-β-stimulated myofibroblast differentiation generates a cascade of perturbations of 
metabolic reactions, gene regulatory circuits and signalling pathways. Although 
genome-scale models have evolved considerably in recent years, it is impossible at the 
present time for such a model to capture all of these genetic and metabolic 
perturbations. This is mainly because of the lack of data regarding kinetic, metabolic 
parameters and enzymatic processes. For instance, even if all the enzymatic parameters 
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were determined in vitro, little is known about their post-translational modifications 
(Pfau et al. 2011). These models capture the GPR (gene-protein-reaction) relationship, 
rely almost entirely on stoichiometry and can predict steady-state flux distributions of 
the metabolic reactions. Further limitations of genome-scale metabolic models are 
discussed in section 5.2. However, these models can successfully identify critical 
metabolic pathways and analyse the effect of certain genetic perturbations on these 
pathways. Even though they do not capture the dynamics of metabolism in cells, they 
represent a very useful map of metabolism. As is mentioned earlier in the thesis, 
metabolic reprogramming in fibrosis has been less studied in vivo. The model confirmed 
the results from in vivo studies which dealt with augmented glycolysis and excessive 
collagen synthesis in IPF. Furthermore, the model confirmed the importance of the 
serine-glycine biosynthetic pathway for collagen production and the up-regulation of 
the enzymes involved in this pathway. These four enzymes can therefore be considered 
potential drug targets in IPF. To the best of the author’s knowledge, this pathway has 
only recently been considered as potential drug target and only a few studies have 
investigated it in detail (Nigdelioglu et al. 2016, Selvarajah et al. 2019).  
In summary, the results published here suggested that TGF-β stimulates cell 
proliferation and collagen synthesis. The FBA results also suggested that FBTGF display 
augmented glycolysis during proliferation which is not confirmed by DEA but in full 
agreement with the already mentioned in vivo studies. Lastly, the simulations showed 
that de novo synthesis of serine and its conversion to glycine constitutes a critical 
metabolic pathway for collagen synthesis in FBTGF which is confirmed by both DEA and 
in vivo experiments. Overall, it can be concluded that the use of genome-scale metabolic 
models combined with constraint-based analysis methods is likely to be an important 
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tool in contributing to the design of therapeutic targets against many conditions 


















Chapter 4: Reconstruction and analysis of skeletal muscle cell using 
constraint-based methods 
Having established the CBMs for FBTGF and FBN, the next step was to extend the 
modelling utility to another contractile cell. This chapter describes a metabolic model 
for skeletal muscle which was constructed and analysed using constraint-based 
methods. Model analysis focused on investigating the effects of hypoxia and AA 
supplementation on protein synthesis rate in the skeletal muscle cell. 
4.1 Introduction 
In response to physical activity (specifically resistance exercise) and nutrient availability, 
muscle hypertrophy occurs. Myofibres increase in size, driven by a net protein balance. 
However, as was outlined in the introductory chapter, in humans, muscle hypertrophy 
is determined by an increase in protein synthesis rather than a decrease in protein 
breakdown. Muscle atrophy, which occurs in conditions such as immobilisation or aging, 
is associated with a reduction in protein synthesis (de Boer et al. 2007). The loss of 
muscle mass can also occur in mountain climbers, specifically for lowlanders sojourning 
at high altitudes (Boyer et al. 1984). Although hypoxia has been reported to blunt the 
increase in myofibrillar protein synthesis rate after resistance exercise (Etheridge et al. 
2011), the mechanisms leading to the loss of muscle mass at high altitude remain 
unclear and the impact of high-altitude hypoxia on the protein synthesis rate has not yet 
been fully understood (Holm et al. 2010). In this chapter, the skeletal muscle cell’s 
metabolic response to hypoxia was investigated using CBM methods with a focus on 
protein synthesis rate. By contrast to hypoxia, dietary supplementation with certain AAs 
stimulates protein synthesis rate and may aid the growth of muscle induced by exercise 
(O'Bryan et al. 2019), yet aspects of this process remain unclear. Hence another aim was 
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to investigate whether supplementation with certain AAs in silico would have the same 
effect on protein synthesis as during in vivo experiments and to identify novel 
combinations of AAs that would stimulate protein synthesis.  
4.2 Methods 
In this section, the components that are appropriate for both hypoxia and AA 
supplementation are provided, and where appropriate, it is made clear to which specific 
process a component of the methods pertains. 
4.2.1 Initial model generation 
Publicly available RNA-seq transcriptomics data for skeletal muscle tissue were 
downloaded from (ArrayExpress https://www.ebi.ac.uk/arrayexpress/experiments/E-
MTAB-2836). RNA-seq analysis was performed as in (Uhlén et al. 2015). Ensembl IDs 
were converted to corresponding Entrez Gene IDs using BiomaRt package in R.  A cut-
off value of 1 was chosen based on sensitivity analysis for the TPM values. Those genes 
with a TPM greater than 1 were called present and assigned 1, while those with TPM 
less than 1 were called absent and assigned -1. Apart from that, the model was built 
using almost identical methods as for FBTGF and FBN models. The FASTCORMICS workflow 
and GPRs in Recon 2.2 were used to generate a context-specific model for the skeletal 
muscle cell. COBRA Toolbox and MATLAB were used in this step. 
4.2.2 Manual refinement 
A manual refinement of the model was performed as described in section 2.2.6.  The 
reactions for actin, myosin and acto-myosin complex building were added to the 
essential reactions set and “forced” into the model. The exchange reactions for proline, 
threonine, tryptophan, histidine and phenylalanine, were manually added to the model 
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as they were not picked up by FASTCORMICS in the initial model. Out of these reactions, 
proline is the only non-essential AA. However, it was reported to be imported in the 
muscle cell, thus the import of proline was made available and an uptake rate was 
considered. As it was mentioned earlier in the paper, the goal was to create a data-
driven model which is consistent with the literature, rather than a model based entirely 
on omics data. The uptake/secretion constraints for AAs, oxygen glucose, lactate and 
lipids were derived from literature: oxygen, glucose, lactate, palmitate (Turcotte et al. 
1998), AAs (Baños et al. 1973). Rat muscle data was used in this case. The chosen unit 
for flux data was µmol min-1 g-1 muscle. This is a common unit for measurements 
performed in vitro on muscle tissue. Where necessary, transformations were performed 
to obtain this unit. 
4.2.3 Modelling assumptions 
FBA and FVA were the principal constraint-based modelling tools that were used for all 
the simulations. Before we performed these simulations, a couple of assumptions were 
made: Firstly, the model was considered to be in steady state. The reason for this 
assumption is related to basic constraint-based modelling approaches and was further 
discussed in the Chapter 1. Secondly, the contractile unit was considered to be made up 
of the two major proteins actin and myosin to form Acto-Myosin complex. Troponin and 
tropomyosin were not included in the reaction. And finally, it was assumed that the 
skeletal muscle cell has already all the hormones available to facilitate muscle growth. 
4.2.4 Model analysis 
4.2.4.1 Studying the Effects of Hypoxia on Protein Synthesis 
Using FBA, the maximal flux rate of myofibrillar protein synthesis was evaluated while 
progressively decreasing the oxygen uptake rate. To represent hypoxia in CBM, the 
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oxygen uptake rate is usually reduced to 10% of the normal uptake rate (Eyassu et al. 
2017). Hence oxygen consumption was reduced to 10% of its normal value and was 
progressively dropped to 0% (anoxia) to investigate the impact of oxygen reduction on 
the objective function (protein synthesis rate). As certain enzymes were reported to be 
either up-regulated or inhibited in hypoxia, FBA was also used to evaluate the fluxes of 
reactions catalysed by these enzymes under normoxic and hypoxic conditions and 
investigate the metabolic pathways leading to these changes. Finally, flux spans and FVA 
were used to assess the role of certain reactions to hypoxic performance of the cell.  As 
glucose uptake is supressed when fatty acids are consumed, these investigations were 
initially performed without fatty acid uptake so that glycolytic fluxes under normoxia 
and hypoxia can be compared.  
4.2.4.2 Studying the effects of AA supplementation on protein synthesis 
Using FBA, the effect of single EAA supplementation on the maximal protein synthesis 
rate was assessed. The lower bound of each EAA was relaxed (one at a time) and the 
Acto-Myosin building reaction was optimised. In this framework, “relaxed” means that 
the lower bound for the uptake rate is set to -1000. Next, using the same methods, the 
effect of BCAA (leucine, isoleucine, and valine) supplementation was evaluated. This 
time, the constraints were “relaxed” simultaneously for each of the three BCAAs to 
ensure they are supplemented in combination. Further, the effects of multiple 
supplementation (with all possible combinations of EAAs) on protein synthesis rate were 
evaluated. And finally, the results were compared with literature data. It is important to 
mention that prior to all simulations the lower bounds were considered equal to -1000 
and for the non-essential AAs (influx was allowed). For multiple EAA supplementation a 
“Power Set” containing all EAA exchange reactions was generated. In mathematics, a 
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power set contains all the subsets of a given set A including the empty set and the initial 
set itself. For instance, for a set A = {a,b,c} the Power Set, denoted as P(A), is 
{{∅};{a};{b};{c};{a,b};{a,c};{b,c};{a,b,c}}. If a given set contains n elements the number of 
elements in the power set is 2n. For 9 EAAs the Power Set will contain 512 combinations 
including the empty set. An algorithm was developed to relax the constraints in all 
possible combinations for the EAAs exchange reactions and sort all combinations in 
ascending order based on their impact on the protein synthesis rate. MATLAB was used 
in this step. 
4.3 Results 
This section divides the results into three subsections: a general model description, the 
evaluation of the effects of hypoxia on skeletal cell metabolism and protein synthesis 
rate and the evaluation of the impact of AA supplementation on protein synthesis rate 
in skeletal muscle. 
4.3.1 Model description 
The final version of the skeletal muscle model was made publicly available (GitHub 
Repository https://github.com/andreidob91/cobramodels). It accounts for 1673 genes 
and 1368 reactions. These reactions account for 65 metabolic functions (subsystems). 
The model also contains 910 metabolites distributed over 9 compartments. Figures 4.1 
and 4.2 detail the reaction and metabolite compartmentalisation in the model. Cytosol 
contains the greatest number of metabolites in the model, followed by mitochondria. In 
terms of reaction distribution over metabolic processes, the highest number of reactions 




Figure 4.1 Compartmentalisation of metabolites in the skeletal muscle model 
This bar chart shows the cellular compartments in the skeletal muscle model sorted by the 




























Figure 4.2 Reaction distribution over metabolic processes in the skeletal cell model 
This bar chart shows the metabolic processes in the skeletal muscle model sorted by the 
number of reactions in each metabolic process.  
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4.3.2 Hypoxia and protein synthesis 
Initially, the ATP production was assessed in normoxia, hypoxia and anoxia. When the 
oxygen uptake rate reached 10% of its normal value, the maximal ATP production rate 
was reduced by 88%, while in anoxia, the maximal ATP production rate dropped by 97% 
(Fig. 4.3). The small flux for maximal ATP production in anoxia was maintained entirely 
by glycolysis. Next, the model was optimised for protein synthesis. When oxygen 
availability was reduced to 10% of its normal value, the protein synthesis carried on at 
the normal rate. Only when the oxygen uptake rate approached 4.2% of the baseline 
value, the protein synthesis started to decrease until it reached 38% of its normal value 
in anoxia. The results showed that a severe reduction in oxygen uptake clearly reduced 
the protein synthesis rate in the skeletal muscle model (Fig. 4.4). Next, metabolic 
pathways leading to this reduction in protein synthesis rate were investigated. As the 
protein synthesis rate only started to drop at 4.2% oxygen, the analysis was performed 










Figure 4.3 The relationship between ATP production and oxygen uptake in the skeletal muscle 
model 
FBA was employed to calculate the maximal flux rate for protein synthesis while the oxygen 




Figure 4.4 The relationship between protein synthesis and oxygen uptake in the skeletal muscle 
model 
FBA was employed to calculate the maximal flux rate for protein synthesis while the oxygen 
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Unsurprisingly, it was found that reactions associated with the electron transport chain 
(part of oxidative phosphorylation) had a lower flux in hypoxic conditions. As the model 
lies in the steady state and TCA cycle provides NADH to oxidative phosphorylation, the 
fluxes in the cycle were reduced too. It is important that both under hypoxia and 
normoxia, the carbon skeleton of valine is degraded by several pathways to produce 
succinyl-CoA which is further used in the TCA cycle. Under normoxia, the oxidation of 
valine is reduced and in consequence, the amount of succinyl-CoA which enters in the 
TCA cycle is also diminished. It is worth mentioning that under normoxia, the lower 
bound for valine uptake was hitting their limits as the valine influx was used for both 
valine degradation and protein synthesis equation. However, in hypoxia, the valine 
oxidation is reduced hence the reduction in valine influx. Lastly, the glucose uptake and 
fluxes through glycolytic reactions were elevated to maintain the amount of ATP which 

























Table 4.1 Flux rates during normoxia and hypoxia (2% oxygen) in the skeletal muscle model when 
optimising for myofibrillar protein synthesis 
Reaction Flux rate (µmol min-1 g-1 muscle) 
Normoxia Hypoxia 
Glucose Uptake 0.0204 0.0425 
HK 0.0204 0.0425 
GPI 0.0204 0.0425 
PFKM 0.0204 0.0425 
ALDOA 0.0204 0.0425 
TPI 0.0204 0.0425 
GAPDH 0.0408 0.0850 
PGK 0.0408 0.0850 
PGAM 0.0408 0.0850 
ENO 0.0408 0.0850 
PKM 0.0408 0.0850 
Lactate Efflux 0.0325 0.0816 
PDH 0.0117 0.0058 
LDHA 0.0441 0.0874 
LDHB 0.0117 0.0058 
CS 0.0095 0.0058 
ACO2 0.0095 0.0058 
IDH3 0.0045 0.0019 
IDH2 0.0050 0.0039                      
OGDH 0.0061 0.0032 
SUCLA1 0.0105 0.0058 
SDHA 0.0105 0.0058 
FH 0.0105 0.0058 
MDH2 0.0140 0.0084 
UQCR10 0.0770 0.0417 
NDUFA10 0.0701 0.0313 
ATP5F1B 0.1748 0.0939 
COX 0.0385 0.0208 
*The maximal flux rates for glycolytic fluxes (yellow), lactate processing fluxes (blue), TCA cycle 






When the protein synthesis objective function is maximised, due to certain proportions 
of each AA in the equation, some of these AAs will become rate-limiting. This is the case 
for alanine which becomes a limiting AA for protein synthesis. Hence with not enough 
import for alanine in the model, glutamine, which is used to produce alanine has its 
corresponding exchange reactions hitting its limits. The import of glutamine is used 
entirely to produce alanine. However, some glutamine is also used in the protein 
synthesis reaction hence it needs to be synthesised internally. Thus, oxaloacetate is used 
in aspartate transaminase to produce mitochondrial aspartate which is transported to 
cytosol. The cytosolic aspartate is then used to produce glutamate. Some of glutamate 
will go in the protein synthesis reaction, while the remaining is used to produce 
glutamine. Asparagine synthetase (glutamine hydrolysing) uses glutamine, ATP, water 
and aspartate to produce glutamate. Glutamate is then used in the protein synthesis 
reaction. Furthermore, in hypoxia, the TCA cycle and malate-aspartate shuttle are 
considerably reduced, and this leads to a reduced production of aspartate. With 
insufficient ATP to maintain the flux, the production of glutamate is also reduced. It is 
important to point out that under hypoxia, no glutamine is used to produce alanine and 
the entire amount of glutamine which is imported through the exchange reaction is used 
directly in the protein synthesis reaction (Fig. 4.5 a-b). 
Furthermore, in normoxia, with enough alanine to support maximal protein synthesis, 
alanine transaminase uses alanine and α-ketoglutarate to produce glutamate and 
pyruvate. Pyruvate is then used in the PDH reaction to replenish the TCA cycle with 
acetyl-CoA. However, in hypoxia, ATP production and flux through the TCA cycle are 
reduced hence the internal production pathways for alanine are also affected. Most of 
the alanine is prioritised for protein synthesis and the flux for alanine transaminase is 
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reduced. However, pyruvate accumulates from the elevated glycolysis. This amount of 
pyruvate needs to be degraded or used by the model. Lactate dehydrogenase consists 
of two subunits: LDHA and LDHB. The first one has a higher affinity for pyruvate, 
converting pyruvate to lactate and NADH to NAD+ in anaerobic conditions, while the 
second one has a higher affinity for lactate converting lactate to pyruvate and NADH to 
NAD+ in aerobic conditions. Under normoxia, the entire amount of cytosolic pyruvate is 
converted to cytosolic lactate, which is further transported to mitochondria and 
converted to mitochondrial pyruvate by LDHB. Then, the mitochondrial pyruvate is 
converted to acetyl-CoA by PDH. In this scenario, there is no need for lactate to be 
secreted out of the model as the entire amount of pyruvate is converted to lactate and 
acetyl-CoA. LDHA was considerably elevated in hypoxic conditions, and the exchange 
reaction for lactate (lactate secretion) starts to pick up as oxygen level drops (Fig. 4.6). 
LDHA also allows the removal of NADH that was not oxidised due to the limited capacity 
of oxidative phosphorylation. Thus, most of the pyruvate is converted to lactate, the 
NADH is oxidised, lactate is secreted through lactate exchange and PDH is reduced. 
However, the lactate secretion exchange reaction is constrained (upper bound) and the 
amount of pyruvate exceeds the upper bound. Thus, LDHB will try to convert the 
remaining lactate to pyruvate which is further converted to acetyl-CoA which refuels 
TCA cycle through PDH (Fig. 4.5 a-b). Under hypoxia, this shuttle between LDHA and 
LDHB clearly favours LDHA (higher flux) and PDH flux is reduced when compared to 












Figure 4.5 The metabolic maps describing the TCA cycle and synthesis of rate-limiting AA when 
protein synthesis is optimised during normoxia (a) and hypoxia (b)  
Under hypoxia, the glycolysis is elevated to maintain the ATP levels. Furthermore, most of the 
pyruvate is converted to lactate via LDHA and transported to the extracellular compartment to 
maintain the redox potential. A reduction in the TCA cycle and malate aspartate shuttle leads to 
a lower synthesis of alanine, glutamine and glutamate which are the rate-limiting AAs protein 
synthesis equation. Line thickness and colour (thin grey to bold red) are indicators of the flux 
values (low to high). The reactions which have no data in the model are coloured in orange. 







Figure 4.6 The relationship between lactate secretion and oxygen uptake in the skeletal muscle 
model 
FBA was employed to calculate the maximal flux rate for lactate secretion while the oxygen 
uptake was progressively dropped. 
 
Usually, under hypoxia, alternative carbon sources such as those provided by AAs can 
be used to produce building blocks which normally fuel the TCA cycle. Glutamine is 
converted to glutamate, which is in turn used to produce α-ketoglutarate that fuels the 
TCA cycle (glutaminolysis). Hence transaminase reactions usually work in the opposite 
way under hypoxia, using glutamate or aspartate to synthesise α-ketoglutarate. With 
alanine, glutamine and glutamate acting as limiting factors for the protein synthesis 
reaction and under hypoxia, the synthesis of these non-essential AAs is prioritised over 
the production of α-ketoglutarate. Thus, the recruited reactions from malate-aspartate 
shuttle such as aspartate transaminase are used to produce aspartate which is further 
used to synthesise glutamine and glutamate. Results showed that the oxygen reduction 
impacts protein synthesis, leading to an impaired TCA cycle which reduces the amount 
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Flux spans revealed the model’s reliance on glycolysis to produce ATP in low oxygen 
conditions (Tables 4.2-4.3). Under normoxic conditions, the model prioritises the 
reactions from the mitochondrial AA metabolism. By contrast, under hypoxic conditions, 
glycolytic reactions such as PGK, ENO, GAPDH, PGAM or TPI were ranked as the top 
reactions by flux span. These reactions were considered essential to hypoxic 
performance of the cell. Interestingly, guanylate kinase 1 (GK1) also showed up in the 
top reactions with a small relative flux span when optimising for myofibrillar protein 
synthesis. This reaction uses ATP to produce GDP and ADP. Next, the ADP is transported 
into the mitochondria where it is used in the ATP synthase (ATP5F1B) reaction. The ATP 
synthase reaction allows the hydrogen protons to flow into the mitochondrial matrix. 
These protons are then pumped out of the mitochondrial matrix in the NADH 
dehydrogenase (NDUFA10) and ubiquinol-6 cytochrome c reductase (UQCR10) reactions 
within oxidative phosphorylation. At the same time, the GTP (mitochondrial) is produced 
through SUCLG1 and transported into the cytosol where it is used in the protein 
synthesis reaction. It is important to point out that before its transportation to 
mitochondria, the ADP is synthesised in a few other reactions. In normoxia, these 
reactions include the nucleoside diphosphate kinase 1 (NME). However, under hypoxia, 
with less GTP derived from the TCA cycle, NME is used to produce GTP instead of ADP. 
With ATP production being reduced in hypoxia, FBA showed that GK1 had a lower flux 
compared to normoxia. However, with fewer alternative resources available, the ADP 
production through GK1 becomes even more essential for the network in hypoxia as it 
maintains the flux through NDUFA10 and UQCR10 reactions. Fig. 4.7 a-b describes these 




Table 4.2 Reactions with smallest relative flux span when optimising skeletal muscle model for 
myofibrillar protein synthesis (Acto-Myosin complex) in normoxia 
Rank Rxn Flux Span Value Metabolic Pathway 
1 BCKDHA 0.08 
 
Valine, Leucine, and 
Isoleucine Metabolism 
2 BCAT 0.08 Valine, Leucine, and 
Isoleucine Metabolism 
3 HIBCH  0.08 
 
Valine, Leucine, and 
Isoleucine Metabolism 
4 HADH 0.08 
 
Valine, Leucine, and 
Isoleucine Metabolism 
5 HIBADH 0.08 
 
Valine, Leucine, and 
Isoleucine Metabolism 
6 MCEE  0.08 
 
Valine, Leucine, and 
Isoleucine Metabolism 
7 MMUT 0.08 Valine, Leucine, and 
Isoleucine Metabolism 
8 ALT 0.31 
 
Glutamate metabolism 




10 GK1 0.43 
 
Nucleotides 




12 COX 1.03 Oxidative 
Phosphorylation 













Table 4.3 Reactions with smallest relative flux span when optimising skeletal muscle model for 
myofibrillar protein synthesis (Acto-Myosin complex) in hypoxia 
Rank Rxn Flux Span Value Metabolic Pathway 
1 GK1 0.22 
 
Nucleotides 
3 PGK 0.33 
 
Glycolysis 
4 ENO 0.33 
 
Glycolysis 
5 GAPDH 0.33 
 
Glycolysis 
6 PGAM 0.33 
 
Glycolysis 




8 TPI 0.37 
 
Glycolysis 
9 AK1 0.82 
 
Nucleotides 









12 HIBCH 1.47 Valine, Leucine, and 
Isoleucine Metabolism 
13 HADH 1.47 
 
Valine, Leucine, and 
Isoleucine Metabolism 
14 HIBADH 1.47 
 









Figure 4.7 The metabolic map describing the role of guanylate kinase 1 in the skeletal muscle 
model under normoxia (a) and hypoxia (b) 
GK1 is used to produce ADP. Under hypoxia, the GTP synthesis is prioritised. With fewer resources 
available to produce ADP and in hypoxia, GK1 becomes essential for the maintenance of the 





















4.3.3 AA supplementation  
Firstly, the results showed that in the single supplementation with EAA, lysine was the 
only EAA that slightly increased protein synthesis rate (Fig. 4.8). Lysine becomes the first 
EAA to hit its uptake limits. This is happening for two reasons: i) out of all EAA, lysine is 
the first limiting AA in the protein synthesis equation (Table 4.4); ii) lysine, is not 
synthesised internally by the model and it is imported directly in the objective function 
(Fig. 4.10). The lysine exchange reaction was subjected to robustness analysis to 
investigate the effects of flux alterations on the protein synthesis reaction. As the lysine 
AA is not synthesised internally, the results showed that protein synthesis is entirely 
dependent on the lysine influx and no intake of lysine would lead to zero protein 
synthesis (Fig. 4.9). None of the BCAAs impacted protein synthesis rate in single 
supplementation.  
Next, when a supplementation with the three BCAAs (leucine, isoleucine and valine 
complex) was performed, the maximal protein synthesis rate did not increase either.  
However, when it comes to combinations of EAAs, isoleucine, leucine and valine 
appeared in all combinations that increased protein synthesis rate in skeletal muscle. 
Table 4.6 details the combinations of 1-9 EAAs that augmented protein synthesis rate. 
Apart from lysine and BCAAs, threonine, methionine, histidine and phenylalanine 
proved effective too in increasing the rate of protein synthesis when supplemented in 
combinations. Furthermore, using multiple EAA supplementation, a hierarchy for the 
rate-limiting AAs was obtained. This hierarchy is further discussed in section 4.4.3. The 
metabolic fate of the other EAAs is similar to that of lysine: they are transported from 





Figure 4.8 Single amino acid supplementation results in the skeletal muscle model 
Each essential amino acid was supplemented individually and the maximal protein synthesis rate 
was derived using Flux Balance Analysis. 
 
 
Table 4.4 The lower bounds in the skeletal muscle model vs. the actual uptake/secretion rates 






























 Lb (max uptake 
rate  
mmol h-1 gDW-1) 






Glc -0.0916 1000 -0.0094 N/A 
Gln -1000 1000 -0.0125 N/A 
Ala -1000 1000 -0.0050 N/A 
Arg -1000 1000 -0.0031 N/A 
Asn -1000 1000 -0.0022 N/A 
Gly -1000 1000 -0.0035 N/A 
His -0.0040 1000 -0.0014 N/A 
Leu -0.0112 1000 -0.0051 N/A 
Lys -0.0047 1000 -0.0047 N/A 
Ile -0.0067 1000 -0.0041 N/A 
Met -0.0067 1000 -0.0023 N/A 
Phe -0.0164 1000 -0.050 N/A 
Pro -1000 1000 -0.0370 N/A 
Ser -1000 1000  -0.0034 N/A 
Thr -0.0085 1000 -0.0038 N/A 
Trp -0.0050 1000 4.81 x 10-4 N/A 
Tyr -1000 1000 -0.0020 N/A 
Val -0.0062 1000 -0.0140 N/A 





Figure 4.9 The objective function (protein synthesis reaction) as a function of the lysine exchange 
flux constraint 
The lower bound for the lysine exchange constraint was varied from 0 to -4.7x10-3 and plotted 





Figure 4.10 The metabolic map describing the mechanism by which lysine is used for protein 
synthesis 
Lysine is imported from the extracellular compartment, transported into cytosol and directed to 





Table 4.5 Multiple EAA supplementation in the skeletal muscle model 
Number 
of EAAs 
AA Combination Protein 
synthesis rate 
(10 -5 µmol min-1 
g-1 muscle) 
1 Lysine 2.37 
2 Lysine, Isoleucine 2.95 
3 Lysine, Isoleucine, Valine 3.22 
 
4 Lysine, Isoleucine, Valine, Leucine 3.23 
 
5 Lysine, Isoleucine, Valine, Leucine, Threonine 4.26 
 








8 Lysine, Isoleucine, Valine, Leucine, Threonine, 
Methionine, Histidine, Phenylalanine 
15.1 
 
*The essential amino acids were supplemented in all possible combinations to identify the most 
optimal combination that could increase protein synthesis rate. This table also ranks (ascending) 







Having divided the Results section (4.3) into three subsections, the Discussion section is 
also divided in this way. 
4.4.1 Model generation 
The skeletal muscle cell model was constructed using publicly available RNA-seq data. 
These data were obtained from an integrative “omics” study of the human proteome 
(Uhlen et al. 2015). In this study, samples of all major tissues and organs in the human 
body were used and RNA-seq was performed for 32 tissues. Data pertaining to skeletal 
muscle cell were downloaded and used to build the model as described in section 4.2.1. 
The current model captures the metabolism for the main macronutrients (AAs, 
carbohydrates, lipids) and micronutrients (vitamins) in the skeletal muscle cell. It 
contains 910 metabolites corresponding to 9 cell compartments and 1368 reactions 
distributed over 65 metabolic processes (Fig. 4.1- 4.2). Among these reactions, transport 
and extracellular reactions have the greatest proportion of total reactions (21.4%), 
followed by fatty acid oxidation (12.4% of total reactions). These numbers for the 
reaction distribution in skeletal muscle model are very similar to those associated with 
FBTGF (myofibroblast). Whilst a direct comparison between the models of the two 
different cell types would be interesting, it is challenging because of the innate 
differences in their metabolic behaviour. However, it is interesting that both models 
predict that fat oxidation is the second largest contributor in terms of the number of 
reactions in the model. The large proportion of reactions involved in fatty acid oxidation 
might reflect the contractile phenotype of the two cells. 
A CBM for skeletal muscle already exists (Nogiec et al. 2013). This model version is 
smaller in size and less developed from a metabolic point of view when compared to the 
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current model. The CBM proposed in 2013 has 341 metabolites, 374 reactions and it was 
aimed at capturing only the macronutrient metabolism. However, the contractile 
complexes for Type 1, 2a, 2x, and 2b myosin heavy chain isoforms were considered in 
the previous model, while the current model only contains Type 1 myosin isoforms. It is 
important to point out that myosin Type 2b is not expressed in human muscle 
(Bloemberg et al. 2012). Furthermore, the contractile unit contains troponin and 
tropomyosin together with actin and myosin, whereas the model proposed in this thesis 
contains only the two major proteins (actin and myosin). Thus, the previous model 
version is more developed with regards to the proteins which are part of the contractile 
unit. However, with the majority of contractile unit being comprised of actin and myosin, 
the production of Acto-Myosin complexes has successfully served as the main objective 
function (as described in section 2.2.7.3) for investigating the effects of hypoxia and AA 
supplementation on protein synthesis in the current skeletal muscle model. 
4.4.2  Hypoxia  
Protein synthesis is an energy dependent process and cells use energy in the form of 
ATP and GTP. Generally, low oxygen reduces the amount of ATP produced by the cell 
and protein synthesis drops.  ATP can be synthesised either anaerobically through 
glycolysis to lactate, or aerobically through oxidative phosphorylation. Oxidative 
phosphorylation takes place in mitochondria and represents the principal source for 
substantial ATP production. Hypoxia blunts oxidative phosphorylation, and this leads to 
a greater reliance on (anaerobic) glycolysis to produce ATP. Furthermore, glucose as an 
anaerobic energy source is more oxygen efficient than fatty acids, hence a switch to 
glucose as an anaerobic energy source is another common feature of the hypoxic 
response. Most, if not all, organisms adapt to hypoxic conditions. However, those that 
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have evolved specifically to deal with low oxygen conditions may have cell-level 
adaptations. For instance, a study published in 1996 (Hochachka et al. 1996) reported 
that sea turtles are able to conserve oxygen by prioritising some vital ATP-consuming 
processes while reducing others, a feature not seen in rats. Furthermore, tumours, in 
which hypoxia is very common, are reported to find alternative pathways to produce 
ATP (Masoud et al. 2015). The discovery of hypoxia inducible factor HIF-1α (Semenza et 
al. 1994) provided further evidence for this metabolic switch from anaerobic to aerobic 
glycolysis. HIF-1α, a subunit of HIF-1 (hypoxia inducible factor 1), is a transcriptional 
factor that plays a crucial role in the organism adaptation to hypoxia. Under normoxic 
conditions, HIF-1α protein has a very short life of less than 5 minutes (Huang et al. 1998), 
but it accumulates quickly under low oxygen conditions (Salceda et al. 1997). It was 
reported that HIF-1α up-regulates several glycolytic enzymes during hypoxia (Kim et al. 
2006, Solaini et al. 2010). These studies also reported that HIF-1α inhibits PDH enzyme 
which converts pyruvate to acetyl coenzyme A (acetyl-CoA). This is done by inducing the 
expression of PDK1, an isoform of pyruvate dehydrogenase kinase, which is a PDH 
inhibitor. Thus, acetyl-CoA is not allowed to enter in the TCA cycle while anaerobic 
glycolysis is elevated. In consequence, TCA cycle is supressed while pyruvate is 
converted to lactate via LDH.  
The results from FBA showed that hypoxia significantly reduced ATP production. In 
anoxia, a small amount of ATP was produced through glycolysis. Similarly, the results 
from FBA showed that protein synthesis rate was considerably reduced in anoxia but 
not completely supressed as even with no oxygen the model will produce a small 
amount of ATP through glycolysis. GTP can be produced using ADP, and the direct import 
of AAs can be used to maintain some protein synthesis flux. Protein synthesis was not 
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reduced at 10% oxygen uptake and it started to gradually decrease only when oxygen 
uptake reached 4.2% of its normal value. It is also worth mentioning that representing 
hypoxia as a 10-20% reduction in the oxygen uptake rate is a common method in CBM 
(Edwards et al. 2014, Eyassu et al. 2017) but not entirely accurate. The relationship 
between oxygen concentration and oxygen consumption rate is closely related but the 
extent to which the rate of oxygen consumption decreases in response to progressive 
hypoxia is still debatable (Cobbs et al. 2018). It was reported that for some animals, the 
decline in oxygen consumption in relation to increased hypoxia is not linear (Cobbs et 
al. 2018). Moreover, the oxygen levels vary between tissues (McKeown 2014). 
In hypoxia, due to low oxygen conditions, electron transport reactions and the TCA cycle 
were considerably reduced. Unsurprisingly, glycolytic fluxes were elevated as the model 
was trying to produce enough ATP to sustain protein synthesis. Glucose consumption 
also increased. In vivo studies have reported an increase in glucose uptake by 2-3 fold 
(Zierath et al. 1998) under hypoxic conditions. With lactate accumulating highly, the 
model converts most of the pyruvate to lactate which is secreted out of the model 
through lactate exchange reaction. As the amount of converted lactate exceeds the 
lactate secretion upper bound, the rest of cytosolic lactate is transported to 
mitochondria and then converted to mitochondrial pyruvate which is further converted 
to acetyl-CoA. 
The elevation of LDHA under hypoxia is confirmed by the in vivo studies. Further, the 
flux rate for PDH is reduced in hypoxia compared to normoxia which is also partially 
consistent with the in vivo studies. However, HIF-1 is reported to inhibit the activity of 
PDH enzyme hence pyruvate is not converted to acetyl-CoA under hypoxia.  Due to the 
limitations of the modelling work which is not able to capture the transcriptional 
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changes that are responsible for the inhibition of PDH by HIF-1, results only show a 
reduction in the flux rate for PDH. 
The protein synthesis equation is limited by the availability of AAs in adequate ratios. 
Thus, certain AAs such as alanine become rate-limiting for protein synthesis equation. 
Alanine synthesis involves the use of other AAs which also become limiting factors in the 
protein synthesis reaction. In theory, non-essential AAs such as alanine should be 
produced internally by the model. The carbon skeletons for these AAs could be obtained 
from glycolysis or from intermediates in the TCA cycle. At the same time, pre-existing 
AAs can be broken down into an α-amino group and their carbon skeletons. Next, the α-
amino group could be used to form new AAs through transaminase reactions. Although 
transaminase reactions are used to produce non-essential AAs, they are using the α-
ketoglutarate or pyruvate fluxes, which, under hypoxia, are considerably reduced or 
prioritised for the replenishment of the TCA cycle. Hence the need for external provision 
of certain AAs through exchange reactions. Furthermore, the model lacks the reactions 
that should get rid of the remaining carbon skeletons which makes the synthesis of the 
non-essential AAs less possible.  
A reduction in aerobic ATP production is considered the main driver for the reduction in 
protein synthesis under hypoxic conditions. However, in this case, the reduction is also 
attributed to an impaired synthesis of the building blocks of the protein synthesis 
equation owing to a reduction of aerobic ATP synthesis and TCA cycle. Under hypoxia, a 
trade-off between resources is employed by the model to support the production of the 
building blocks of the protein, TCA cycle and ATP production. Understanding this trade-
off is challenging and the extent to which this trade-off plays a role biologically remains 
to be determined.  
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FVA and flux spans showed that, under hypoxic conditions, glycolytic fluxes outranked 
the electron transport chain reactions showing that in the absence of oxygen the model 
is forced to produce ATP through anaerobic glycolysis. Interestingly, GK1 also came up 
in the top reactions. In hypoxia, GTP production is prioritised over the synthesis of ADP 
which is further used to generate precursors for the reactions within oxidative 
phosphorylation. Hence the ADP synthesis via GK1 becomes essential for the network. 
With palmitate uptake being active, FBA also showed that, under hypoxic conditions, 
the fatty acids (palmitate) uptake is supressed. Fatty acids such as palmitate were used 
by the model in the fatty acid β-oxidation (FAO) which provides acetyl-CoA for TCA cycle 
and co-enzymes NADH and FADH2 that enter in the electron transport chain. As both 
the electron transport chain and TCA cycle are considerably reduced during hypoxia, 
both the fatty acid consumption and oxidation are ceased. It was reported that hypoxia 
reduces fatty acid oxidation (Morash et al. 2013) and fatty acid uptake (Musutova et al. 
2018) in muscle cells. When fatty acid uptake is in place and under normoxic conditions, 
glucose uptake and glycolysis are supressed when optimising for myofibrillar protein 
synthesis. The relationship between fatty acids and glycolysis in muscle has been studied 
for many years. In a study based on rat muscle, published in 1963, the authors used the 
term “glucose and fatty acids cycle” and proposed a hypothesis that glucose and fatty 
acids “compete” for mitochondrial oxidation and this results in glucose uptake being 
reduced when fatty acids are present (Randle et al. 1963). Some more recent studies 
concluded that free fatty acids inhibit glucose transport and phosphorylation in human 
skeletal muscle (Krebs et al. 2001, Roden 2004). However, under hypoxia, glycolysis is 
once more utilised and fatty acid oxidation is ceased. This is in full agreement with 
studies confirming that during hypoxia the cell favours glucose uptake over fatty acid 
utilisation, and makes perfect sense from a modelling point of view: Under normoxic 
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conditions the model has sufficient oxygen for fatty acid oxidation, which increases the 
amount of acetyl-CoA, NADH and FADH2, precursors for TCA and oxidative 
phosphorylation. Thus, anaerobic glycolysis is not needed at all for the ATP production. 
When oxygen becomes limiting, the model can only run anaerobic glycolysis to produce 
ATP. It has been reported that under hypoxia, skeletal muscle cell favours glucose 
uptake over fatty acids utilisation (Horscroft et al. 2014). 
Cells respond to hypoxia by reprogramming their metabolic pathways. The aim was to 
investigate these metabolic changes which impact protein synthesis rates in skeletal 
muscle. Although the model did not capture the transcriptional reprogramming of 
skeletal muscle during hypoxia, most of the metabolic pathways associated with this 
transcriptional reprogramming were clearly described by the simulations. The results 
showed that, in the absence of oxygen, the cell adapts its metabolism to produce the 
AAs in adequate proportions and synthesise ATP anaerobically through glycolysis. The 
model also prioritises the production of GTP over ADP synthesis to maximise protein 
synthesis. 
In conclusion, the results showed that a considerable reduction in oxygen uptake causes 
a decline in protein synthesis rate which might provide the context for muscle wasting 
at high altitudes. However, it must be remembered that muscle mass is determined by 
the balance between protein synthesis and degradation and this model only focuses on 
the synthesis component. Furthermore, as it was outlined in the introductory chapters, 
beside a reduction in oxygen tension at high altitude, other factors such as reduction in 
appetite can influence the protein synthesis rate in muscle. 
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4.4.3 AA supplementation 
It is still controversial whether supplementation with certain AAs can increase protein 
synthesis in muscle and if they can, which is the best combination that can trigger 
anabolic responses and increase protein synthesis rate.  The model focused on single 
and multiple supplementation with EAAs to identify the relevant combinations. Non-
essential AAs were left unconstrained as we were only interested in the EAA 
supplementation. A study published in 1998 showed that supplementation with non-
essential AAs has no effect on the protein synthesis rate, while only supplementation 
with EAAs increased protein synthesis (Smith et al. 1998).  
Single amino supplementation with EAAs showed that lysine was the only EAA that 
slightly augmented myofibrillar protein synthesis rate in skeletal muscle cell. A study 
reported that supplementation with combinations of EAAs including lysine increased 
protein synthesis rate in muscle (Tipton et al. 1999). It has also been reported that single 
supplementation with certain EAAs, including lysine, generated similar anabolic 
signalling pathways to valine and isoleucine (Atherton et al. 2010). In the current model, 
due to the proportion of lysine in the actin and myosin proteins and the lysine uptake 
rate derived from literature, the simulations suggested that supplementation with lysine 
alone can slightly increase the protein synthesis rate. These models rely on 
stoichiometry and the goal was to identify those EAAs which have the greatest weight 
on the protein synthesis equation based on their uptake rate which was derived from 
literature. Most probably, further experiments are needed to confirm the impact of 
lysine on protein turnover and muscle growth.  When it comes to BCAAs, FBA showed 
no increase in the maximal protein synthesis rate when supplemented in combination 
of three (leucine, isoleucine and valine). Even though several reviews (Blomstrand et al. 
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2006, Norton et al. 2006) reported that BCAA supplementation leads to either increased 
protein synthesis or decreased protein degradation rate through activation of mTOR 
signalling pathways, there are also a number of studies that showed that 
supplementation with the BCAA alone has no anabolic effect (McNurlan et al. 1982, May 
et al. 1989, Louard et al. 1990). The model cannot capture the genetic control at 
transcriptional or translational level. Thus, it is impossible to assess the role of BCAAs in 
activating certain signalling pathways. However, when we performed multiple 
supplementation in combination, a supplement of lysine, leucine, isoleucine and valine 
increased protein synthesis rate. Thus, the model predicts that lysine is missing from this 
rate-limiting combination. It is uncertain whether supplementation with lysine and 
BCAAs is optimal for an increased protein synthesis rate and clearly further experimental 
work is needed to confirm this hypothesis. However, it was reported that 
supplementation with BCAA alone might not be enough to achieve maximum protein 
synthesis and other EAAs are needed in combination with BCAA to stimulate myofibrillar 
protein synthesis to near maximal levels (Jackman et al. 2017). Moreover, two studies 
reported that administration of BCAA alone not only was ineffective in stimulating the 
protein synthesis but also reduced it (Louard et al. 1990, Louard et al. 1995). With the 
earlier version of CBM for skeletal muscle (Nogiec et al. 2013) the authors performed 
similar simulations. In single AA supplementation, they reported only methionine to 
increase protein synthesis. Furthermore, they identified the combination of methionine, 
arginine, isoleucine, leucine, and phenylalanine, lysine and threonine (in this order) as 
the most optimal combination for increasing protein synthesis.  
The current results also showed that BCAAs appeared in all combinations of EAAs (2-8) 
that increased protein synthesis rate. Threonine and methionine are also part of the 
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effective combinations of EAAs (5,6). The results also indicated that supplementation 
with a combination of all EAAs except tryptophan would reach the maximal protein 
synthesis rate. Although this result might sound trivial, a study that was previously 
mentioned reported that a supplementation with all essential AAs should be performed 
to trigger an accelerated anabolic response and generate a positive protein turnover 
(Wolfe 2017). 
Apart from finding the “ideal” combination of AAs that can increase protein synthesis in 
skeletal muscle, another goal was to identify the limiting AAs. A rate-limiting AA is a 
particular EAA whose availability determines the maximal rate for protein synthesis. 
Supplementation with rate-limiting AAs is supposed to increase or maximise protein 
synthesis rate. In terms of the rate-limiting AAs, multiple supplementation with EAA 
provided us with a hierarchy: Lysine, BCAA (isoleucine, valine and leucine in this order), 
threonine, methionine, histidine, and phenylalanine. Each of the EAAs provided 
becomes a limiting term for the protein synthesis in this order. Based on the model 
simulations, lysine is the first limiting AA. Lysine is the first and most important limiting 
agent in horses and pigs and is reported to impact protein synthesis and muscle mass in 
these animals (Chang et al. 2005, Liao et al. 2015, Mastellar et al. 2016). Threonine and 
methionine were also reported to be limiting AAs in pigs (Wang et al. 2007). Even though 
in combinations with other EAAs it proved effective in stimulating protein turnover and 
muscle growth in humans, and is considered an essential AA, there is no clear 
experimental evidence to support that lysine is the first limiting AA in humans. However, 




It is important to point out that only EAAs were incorporated in this analysis. As 
discussed in the methods section, the non-essential AAs were made available for this 
analysis through their corresponding exchange reactions. Otherwise, non-essential AAs 
such as glutamine and alanine would also become rate-limiting AAs for protein synthesis 
before any other EAAs. However, this would happen due to certain reasons which were 
discussed in section 4.4.2. Hence the supplementation analysis would be biased by the 
incorporation of the non-essential AAs. This is because in this framework there are two 
types of essentiality for protein synthesis reaction: a “conditional” essentiality for the 
non-essential AAs which is determined by an overall lack of resources (degradation 
pathways, α-amino group etc.) and another type of essentiality for EAAs due to lack of 
synthesis pathways. However, the second type of essentiality has an important 
biological relevance as EAAs are not synthesised in the body and supplementation with 
these AAs is thought to enhance protein synthesis rate in muscle. 
The fact that certain EAAs may be rate-limiting for protein synthesis in the human 
muscle has been discussed for many years and despite many scientific studies focusing 
on this fact, results are still controversial. The current results suggested that BCAAs can 
achieve maximal protein synthesis only in combinations with other EAAs. This is in full 
agreement with studies which reported this hypothesis (Jackman et al. 2017). 
Furthermore, the model predicted certain combinations that can impact protein 
synthesis rate in skeletal muscle cell.  Simulations also showed that, with the exception 
of lysine, which can slightly increase protein synthesis rate in single supplementation, all 
other combinations need BCAA to reach maximal protein synthesis rate. Due to 
controversy surrounding AA supplementation and their impact on muscle growth, I 
acknowledge that further in vivo experiments are required to investigate the model 
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predictions. However, these modelling approaches can pave the way for using systems 
biology and COBRA methods for studying the effects of AA supplementation on muscle 

















Chapter 5: General discussion 
This brief chapter provides a general overview and discussion of the work presented in 
this thesis, limitations of genome-scale CBMs in general, future directions of this area of 
research and future work that can be done to improve the modelling work performed 
in this thesis. 
5.1 Recapitulation 
The work in this thesis was focused on developing and analysing three in silico genome-
scale models for FBN, FBTGF and skeletal muscle cells. The global human reconstruction 
(Recon 2.2) and RNA-seq transcriptomics data were used to generate context-specific 
models. The gene-protein-reaction (GPR) associations in Recon 2.2 were used to identify 
active (core) reactions in the required biological context and FASTCORMICS algorithm, 
an adaptation of FASTCORE, was used to generate context-specific models. The models 
were also manually refined and lower and upper bounds were imposed to limit the size 
of the solution space and improve model contextualisation. Constraint-based methods 
were used to analyse the model outputs, run simulations and generate predictions. RNA-
seq technology was used to generate gene expression data in human lung fibroblast. 
Two datasets were generated: normal (FBN) and TGF-β stimulated fibroblasts (FBTGF). 
The latter one is considered a suitable in vitro model for myofibroblast cells. Two 
separate genome-scale models were derived from these data sets. These models were 
analysed separately using constraint-based methods and then compared. A biomass 
objective function was formulated to simulate proliferation. Furthermore, a collagen 
production reaction was added to the FBN and FBTGF models. Collagen synthesis and 
biomass production were optimised using FBA. FVA and flux spans were used to identify 
the most important reactions involved in collagen production and GEA was used to find 
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essential /critical genes for collagen synthesis. In separate modelling, publicly available 
RNA-seq data on human skeletal muscle was used to build a context-specific model. 
Reactions involved in the muscle building process were added to the model and 
optimised using FBA. The building of the contractile complex (Acto-Myosin complex) 
served as the main objective function to simulate muscle protein synthesis. This model 
was analysed under hypoxic conditions and AA supplementation to assess protein 
synthesis rate. 
FBA results showed that both collagen synthesis and biomass production (proliferation) 
rates are higher in the FBTGF model than in the FBN model. Further, glycolysis rates were 
higher for the FBTGF model. Next, the work focused more on the FBTGF model to 
investigate the effect of TGF-β on collagen synthesis. Among a few other genes, GEA 
identified PHGDG, PSAT, SHTM, PSPH as critical/essential genes for collagen production 
in the FBTGF model. These genes are involved in glycine and serine metabolism, so the 
model has revealed a critical role for glucose-derived serine/glycine biosynthesis as 
collagen intermediates. Furthermore, DEA showed that the genes involved in the de 
novo serine-glycine pathway are up-regulated in FBTGF. Next, in the skeletal muscle 
model, the simulations showed that hypoxia reduced protein synthesis rate and a 
metabolic reprogramming which promotes AA synthesis and glycolysis over 
mitochondrial metabolism. Results also suggested that supplementation with certain 
combinations of AAs, including BCAA, could increase protein synthesis rate and facilitate 
skeletal muscle growth. 
The success of the modelling approach was confirmed by making comparisons with 
experimental data in the literature. These models can be used for further simulations 
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with special attention to drug discovery, nutritional strategies and in silico target 
validation. 
5.2 Limitations of genome-scale CBMs 
Despite many strengths and applications of CBMs at steady state, there are still a 
number of limitations associated with these models. The main limitation is the lack of 
kinetic data. Genome-scale CBMs are purely based on reaction stoichiometry and 
reversibility and the steady-state assumption prevents the representation of the 
dynamic, transient nature of metabolism.  For instance, FBA, the principal tool used for 
analysing CBMs, can only provide a single optimal solution of flux distributions for a 
certain objective function (reaction). Unlike CBMs, kinetic models are based on ordinary 
differential equations (ODE) and incorporate the rates of change for metabolite 
concentration as well as enzyme kinetic parameters. CBMs do not contain any 
information regarding metabolite and enzyme concentrations. Furthermore, these 
models cannot capture the effect of substrate concentration on enzyme activity as they 
lack enzymatic parameters such as Michaelis constant (Km) or maximal velocity (vmax). 
Further, when GEA is used to determine genes that are essential to a certain objective 
function (reaction), there is no information available about the regulatory changes that 
are associated with the deletion of those genes. However, integrating these parameters 
simultaneously into the high-throughput data is a difficult task and more advanced 
modelling methods are needed to achieve this objective.  
5.3 Future directions 
Given the limitations mentioned in the previous section, there are several ways to 
improve traditional genome-scale CBMs and bridge the gap between dynamic models 
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and genome-scale CBMs at steady state. To some extent, this section follows the logical 
approach proposed by Martins Conde Pdo et al. (2016).  
Future developments of CBMs are based on two directions: integration of kinetic and 
regulatory parameters with current CBM methods and coupling multi-cellular or multi-
tissue CBMs, the ultimate goal being the construction of a multi-cellular human kinetic 
model (Martins Conde Pdo et al. 2016). Even though this goal is far from being 
accomplished mainly due to the differences between kinetic and genome-scale CBMs, 
some progress was achieved to bring these two approaches together. For instance, 
several tools were developed to improve traditional FBA.  FBA-derived tools such as 
regulatory FBA or rFBA (Covert et al. 2001), dynamic FBA or dFBA (Mahadevan et al. 
2002), integrated FBA or iFBA (Covert et al. 2008), steady-state regulatory flux balance 
analysis or SR-FBA (Shlomi et al. 2007) were designed to integrate transcriptional 
regulation parameters with the traditional FBA using Boolean rules. Furthermore, PROM 
(Chandrasekaran et al. 2010) is an algorithmic tool that uses conditional probabilities to 
define the relationships between genes and transcriptional factors.  In this way the 
regulatory parameters are integrated with the metabolic network. In this framework, 
FBA is only used for optimisation purposes.  In a study published in 2010 (Fleming et al. 
2010), the authors proposed a method to incorporate mass conservation at steady state, 
energy conservation and enzyme kinetics constraints into a single system of equations 
and inequalities. Another approach proposed by Pozo et al. (Pozo et al. 2012) was 
developed to optimise multiple objective functions in non-linear kinetic models. This 
algorithmic tool can be used to identify the global minimum for a metabolite synthesis 
rate while determining a minimum increase in concentration change of intermediate 
metabolites. Another in silico approach developed by Andreozzi et al. (Andreozzi et al. 
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2016) reduces the uncertainty that is usually associated with kinetic parameters and 
identifies the enzymes that should be addressed in order to obtain a desired 
physiological state of the organism. In this section I could only a brief overview of a few 
of the methods that have been developed in the recent years to integrate kinetic and 
regulatory parameters with traditional CBM. Research papers proposed by Martins 
Conde Pdo et al. (Martins Conde Pdo et al. 2016) and Lewis et al. (Lewis et al. 2012) 
provide a more detailed description of further tools that might be used. 
Another future direction of CBMs is the building of multi-cellular or multi-tissue models 
by combining different models. When it comes to combining multiple CBMs, one of the 
main difficulties is dealing with different identifiers for metabolites reactions or genes 
(Pfau et al. 2016). Although, Systems Biology Markup Language (SBML) (Hucka et al. 
2003) was initially designed to facilitate the interrogation of multiple models in a 
standardised format and a lot of effort was put in finding a common language between 
different databases, it is still difficult to deal with model parameters which are derived 
from different databases (Pfau et al. 2011). However, CBMs describing the interaction 
of multiple organisms (Bordbar et al. 2010, Heinken et al. 2013) and multi-tissues within 
the same organisms (Lewis et al. 2010, Bordbar et al. 2011) were constructed. Another, 
and probably most prominent challenge of this area of research is building a whole-body 
metabolic model. Although progression to this goal faces a lot of challenges, some 
attempts of combining CBMs with whole-body physiologically-based pharmacokinetic 
(PBPK) models have been made. PBPK models are used in the pharmaceutical industry 
to describe the absorption, distribution, metabolism, and excretion (ADME) of drugs in 
the human body.  For instance, in a review proposed in 2012 (Krauss et al. 2012) a liver 
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CBM (Gille et al. 2010) was integrated with a whole-body PBMK to investigate the effects 
of tissue metabolic processes at a system level. 
To conclude, the future of genome-scale CBM looks promising and I expect that more 
advanced computational tools will be developed to bridge the gap between CBMs and 
kinetic models. Although the objective of building a whole-body kinetic model for 
human metabolism is far from being met, the direction of travel suggests that this will 
ultimately be achieved.  
5.4 Future work 
It is important to point out that further work could be done to further improve the work 
that was performed in this thesis. Given the ideas and concepts outlined in this chapter, 
one interesting approach would be deriving kinetic parameters and transcriptional 
regulatory constraints and integrate them with the already-built CBMs to further reduce 
the solution space in all models. From a biological point of view, an interesting approach 
for the FBTGF CBM would be building a multi-cell model of lung fibrosis to include 
myofibroblast and lung epithelium metabolism. Then, the approach could be extended 
to intracellular signalling as in (Aurich et al. 2012). This would be useful for interrogating 
epithelial cell biology as this cell type is notoriously difficult to culture/study pre-
clinically and may provide insights into other respiratory diseases (e.g. COPD). 
Moreover, further mechanisms/targets that perturb myofibroblast biology with 
potential to additionally impact non-lung fibrotic diseases (hepatic, renal and cardiac 
fibrosis) could be identified. The overall aim for all of these approaches would be 
predicting important metabolic pathways and candidate drug targets that could become 
useful in treating IPF.  With regards to the skeletal cell CBM, the contractile complex 
(objective function) which is currently formed of only actin and myosin, could be further 
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developed by adding other muscle proteins such as troponin, tropomyosin, titin and 





















6.1 Biomass composition 
Table 6.1.1 
Main Breakdown 
Mass unit: µg 
 
Lipids Protein Sugar DNA RNA Total  
74.45 249 44.82 6 5 379.27 
% Total 19.63 65.65 11.81 1.58 1.31  
 
Protein 
Galacci, Higuchi (1966)  
Lipids 
Macarak, De la Llera et al. (1979), Harzer and Kustermann-Kuhn (2001) 
Sugar 
Umapathysivam, Hopwood et al. (2005) 
DNA 
(Bordbar et al. 2010)) 
RNA 




















Mass Mass % 
Content 
mmol/gDW 
Alanine 0.0552 89.05 4.91 0.0376 0.2774 
Arginine 0.1230 175.11 21.53 0.1648 0.6182 
Asparagine 0.0371 132.05 4.89 0.0375 0.1864 
Aspartic Acid 0.0642 132.04 8.47 0.0648 0.3226 
Cysteine 0.0122 121.02 1.47 0.0113 0.0613 
Glutamate 0.0731 146.05 10.67 0.0811 0.3674 
Glutamine 0.0483 146.07 7.05 0.0540 0.2427 
Glycine 0.0516 75.03 3.87 0.0296 0.2593 
Histidine 0.0459 155.07 7.11 0.0544 0.2306 
Isoleucine 0.0321 131.09 4.20 0.0322 0.1613 
Leucine 0.0635 131.09 8.32 0.0632 0.3191 
Lysine 0.1060 147.11 15.59 0.1193 0.5327 
Methionine 0.0170 149.05 2.53 0.0193 0.0854 
Phenylalanine 0.0309 165.08 5.10 0.0390 0.1553 
Proline 0.0364 115.06 4.18 0.0329 0.1829 
Serine 0.0432 105.04 4.53 0.0347 0.2171 
Threonine 0.0379 119.06 4.51 0.0345 0.1904 
Tryptophan 0.0105 204.09 2.14 0.0164 0.0527 
Tyrosine 0.0239 181.07 4.32 0.033 0.1201 
Valine 0.0438 117.08 5.12 0.0392 0.2201 
 




















Mass Mass % 
Content 
mmol/gDW 
dAMP 0.29 349.23 103.02 0.31 0.0140 
dCMP 0.20 307.19 62.97 0.18 0.0097 
dGMP 0.20 347.22 71.18 0.21 0.0097 
dTMP 0.29 322.21 95.05 0.28 0.0140 
 








Mass Mass %  
Content 
mmol/gDW 
AMP 0.18 345.06 62.45 0.18 0.0070 
CMP 0.27 321.05 88.93 0.26 0.0107 
GMP 0.36 361.06 131.78 0.38 0.0141 
UMP 0.17 322.04 57.00 0.16 0.0068 
 
Mol % Content was derived from East (East 1968) 







Glycogen 0.085 162 0.52 
 














Lipid Fractions % (weight) AVG MW 
Weight 
                      mmol/gDW 
Neutral Lipids 
  
Myristic 0.028 228.37 0.0002 
Palmitic 0.234 256.42 0.0017 
Palmitoleic 0.026 254.40 0.0002 
Stearic 0.29 284.47 0.0020 
Oleic 0.39 282.46 0.0027 
Cholesterol 10.2 386.7 0.0517 
Diglycerides 1.4 615.82 0.0044 




43 791.37 0.1066 
PE 23.3 742.63 0.0615 
Sph 7.4 752.37 0.0193 
PS 6.9 825.38 0.0164 
PI 3.8 865.91 0.0086 
PG 8.9 758.46 0.0230 
LBPA 0.8 430.57 0.0036 
 













ATP Maintenance                                         
 mmol ATP/mmol aa 
Protein synthesis and processing 4.30 
RNA synthesis and processing 0.4 
DNA synthesis and processing 1.37 
Source: (Bordbar et al. 2010)  
 mmol/gDW 
total protein 5.80 
total protein 0.18 
total DNA 0.07 
  





















6.2 Uptake/secretion constraints 
Table 6.2.1: Uptake/Secretion Constraints in the FBN Model 
Exchange reaction Lb (max uptake rate  
mmol h-1 gDW-1) 
Ub (max secretion rate 
mmol h-1 gDW-1) 
Glc -0.5280 0 
Gln -0.0290 1000 
Arg -0.0160 1000 
Asn -0.0041 1000 
Asp -0.0063 1000 
His -0.0032 1000 
Leu -0.0190 1000 
Lys -0.0120 1000 
Ile -0.0130 1000 
Met -0.0049 1000 
Phe -0.0058 1000 
Ser -0.0370 1000 
Thr -0.0084 1000 
Trp -0.0015 1000 
Tyr -0.0046 1000 
Val -0.0140 1000 
Lac 0 0.695 











Table 6.2.2: Uptake/Secretion Constraints in the FBTGF Model 
Exchange reaction Lb (max uptake rate  
mmol gDW-1 h-1) 
Ub (max secretion rate 
mmol gDW-1 h-1) 
Glc -1.056 0 
Gln -0.058 1000 
Arg -0.032 1000 
Asn -0.0082 1000 
Asp -0.0126 1000 
His -0.0064 1000 
Leu -0.0380 1000 
Lys -0.0240 1000 
Ile -0.0260 1000 
Met -0.0098 1000 
Phe -0.0116 1000 
Ser -0.0740 1000 
Thr -0.0168 1000 
Trp -0.0030 1000 
Tyr -0.0920 1000 
Val -0.0280 1000 
Lac 0 1.74 











Table 6.2.3: Uptake/Secretion Constraints in the Skeletal Muscle Model 
Exchange reaction Lb (max uptake rate  
mmol gDW-1 h-1) 
Ub (max secretion rate 
mmol gDW-1 h-1) 
Glc -0.0916 1000 
Gln -0.0017 1000 
Ala -0.0041 1000 
Arg -0.0052 1000 
Asn -0.0008 1000 
Asp -0.0008 1000 
His -0.0040 1000 
Leu -0.0112 1000 
Lys -0.0047 1000 
Ile -0.0067 1000 
Met -0.0067 1000 
Phe -0.0164 1000 
Pro -0.0029 1000 
Ser -0.0076 1000 
Thr -0.0085 1000 
Trp -0.0050 1000 
Tyr -0.0132 1000 
Val -0.0062 1000 
Lac 0 0.0816 
O2 -0.728 1000 
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